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Sphingolipids are a highly diverse category of compounds that serve not only as 
components of biologic structures but also as regulators of numerous cell functions.  Because so 
many of the structural features of sphingolipids influence their biological activity, there is a need 
for comprehensive methods for quantitation of as many individual subspecies as possible.  This 
dissertation describes methods that have been developed and validated for the extraction, liquid 
chromatographic separation, identification and quantitation of sphingolipids by electrospray 
ionization (ESI), tandem mass spectrometry (MS/MS) using an internal standard cocktail 
developed by the LIPID MAPS Consortium.  The compounds that can be readily analyzed are 
sphingoid bases and sphingoid base 1-phosphates, as well as more complex species such as 
ceramides, ceramide 1-phosphates, sphingomyelins, and mono- and di-hexosylceramides.  For 
broader utility, the methods have been optimized for two categories of tandem mass 
spectrometers, a triple quadrupole mass spectrometer and a quadrupole linear-ion trap mass 
spectrometer.  With minor modifications, these methods can be applied to the analysis of isomers 
such as glucosylceramide and galactosylceramide, and with the availability of additional internal 
standards, more complex species such as sulfatides can also be quantified.  Using these methods 
46 species of these compounds have been quantified in RAW264.7 cells, a macrophage cell line. 
Quantitation of individual sphingolipid metabolites is possible using liquid 
chromatography, tandem mass spectrometry, and stable isotope labeling with [13C]palmitic acid 
can be used to differentiate between metabolites produced by de novo synthesis versus turnover.  
This approach is more accurate when one knows the isotope enrichment of the precursor pool (in 
xiii 
 
this case, [13C]-palmitoyl-CoA); therefore this dissertation describes methods to analyze both the 
various isotopic forms of palmitoyl-CoA and sphingolipids through sphingomyelins and 
monohexosylceramides using two cell models, HEK293 cells and RAW264.7 cells treated with 
Kdo2-Lipid A.  The analysis of the fatty acyl-CoA’s followed a fragmentation mechanism 
involving a neutral loss of 507 Da (with the charge residing on the acyl-chain and thioester 
portion of the CoA).  The sphingolipid analysis was simplified by the fragmentation of most of 
the metabolites (sphingoid bases and 1-phosphates, ceramides, and monohexosylceramides) to 
backbone product ions. For example the presence of the isotopic label in the long chain base, N-
acyl linked fatty acid, or both was determined via, m/z 264 for [12C]sphingosine (d18:1) and m/z 
280 for [13C]sphingosine (m+16, d18:1), versus the m/z of the isotopically labeled precursor, 
(m+16 versus m+32).  For sphingomyelins, which poorly fragment to the individual backbone 
moieties, the isotope label can be determined by first treating the samples with phospholipase D 
to produce ceramide 1-phosphates that give the backbone fragments.  Sphingolipid isotope 
metabolic precursor labeling experiments (SIMPLE) give a more accurate estimate of the 
amounts of sphingolipids made from de novo biosynthesis than is possible without isotopic 
labeling, or with use of stable isotopes without estimation of the specific activity of the precursor 
pool. 
The alteration of these existing methods for application to collaborative projects is a 
required task for practical implementation.  Several collaborative scenarios are explored and the 







 Sphingolipids (SL‟s) are a highly diverse category of compounds that serve not 
only as components of biologic structures but also as regulators of numerous cell 
functions.  SL‟s are structural components of cellular membranes in all eukaryotes and 
some prokaryotes and viruses, and are characterized by the presence of a sphingoid base 
in the backbone of their structures. The term „sphingosin‟ originated with Johann 
Thudicum, who used the term in reference to the sphinx-like properties of alkaloidal 
lipids isolated from brain extracts
1
. These enigmatic molecules have continued to 
fascinate and challenge the scientific community after the identification of well over a 
thousand unique SL species
2
.  Recent advances in SL research have refined the 
perception of this class of lipid.  Once regarded as just structural components of 
biological membranes, SL‟s are now known to play important roles in signal 
transduction,
3, 4
 in addition to their structural functions.  SL‟s are currently considered 







.  Because of their involvement in many cellular processes, SL‟s have 









, and stem cell research
24
. 
 The capacity for de novo SL biosynthesis is prevalent in many cells and tissues.  
Cells display a loss of viability in the absence of exogenous sphingoid bases (if they are 
not produced de novo), downregulation of the de novo SL biosynthetic pathway by 
mutation,
25-27
 or inhibition by myriocin
11, 28, 29
 of serine palmitoyltransferase (SPT), the 
first enzyme in the biosynthetic pathway.  De novo SL biosynthesis is widespread in cells 
2 
 
and tissues in vivo most likely due to the degredation of sphingoid bases in the 
mammalian intestine (although SL are present in most foods)
30, 31
.  
  Selected SL‟s and a portion of their de novo biosynthetic and turnover pathways 
are shown in Figure 1.1, including free sphingoid bases (non-acylated, long-chain bases). 
Other species are N-acylated sphingoid bases, and still other species are more complex 
with a polar moiety at the 1-position.  Long-chain sphingoid bases are variations of the 
basic structure: 2-amino-1,3-dihydroxyalkanes with (2S,3R) erythro stereochemistry.  
Sphingoid bases vary from linear 18 carbon alkyl chain containing no sites of 
unsaturation (d18:0), to as short as d14:0 and greater than d22:0, with possible 
unsaturations (most commonly Δ4) for d18:1, d18:2, etc.  This increasing molecular 
diversity results from a series of biosynthetic enzymatic reactions.  Cells exert fine-tuned 
control over SL metabolic flux and opposing outcomes in cellular state may hang in the 
balance: sphingosine and sphingosine-1-phosphate are interconverted by kinases and 
phosphatases 
32, 33
, and in general, the non-phosphorylated sphingoid base is pro-
apoptotic
34
 while the phosphorylated sphingoid base is anti-apoptotic (if produced by 
sphingosine kinase 1
35, 36
 and apoptotic if produced by sphingosine kinase 2
37
).  Studies 
of SL biology clearly require a high degree of specificity for quantitation of multiple 
molecular species in a single sample because of the structural similarity and 
interconversion of SL species.  Thus, the ability to analytically distinguish these species 
is critical for the accurate determination of the amounts and metabolic flux.  
Development of state-of-the-art technologies for SL analysis, along with rigorous regard 
for qualitative and quantitative specificity, are thus required for investigation of 
































































































































































































Figure 1.1  Partial sphingolipid metabolic pathway with structures of selected 
species and numerically designated enzymatic reactions. Enzymes in Figure 1 
correspond to serine palmitoyltransferase – 1, 3-ketosphinganine reductase – 2, 
dihydroceramide synthases – 3, dihydroceramide desaturases – 4, sphingomyelin 
synthases – 5, glucosylceramide synthase - 6, ceramide kinase – 7, lactosylceramide 
synthase – 8, sialyltransferase 1 – 9, sialidase – 10, galactosidase – 11, 
sphingomyelinases (C-type) – 12, ceramidases – 13, β-glucoceramidase – 14, ceramide-
1-phosphate phosphatase (putative) – 15, sphingosine / sphinganine kinases – 16, 





Sphingoid bases (also called long-chain bases) include 3-ketosphinganine, 
sphinganine, phytosphingosine (4-hydroxysphinganine), sphingodienes, and sphingosine 
(also called sphing-4-enine)
45
.  The first product of de novo SL biosynthesis is 3-
ketosphinganine, which is rapidly reduced to sphinganine by 3-keto-sphinganine 
reductase.  In many mammalian cell types, phytosphingosine and sphingosine are the 
products of phytoceramide and ceramide de-N-acylation, respectively, not direct 4-
hydroxylation and 4,5-E-desaturation of sphinganine.  However, yeast cells and some 
mammalian cell types (i.e. intestinal epithelia 
46
) directly synthesize  
4-hydroxysphinganine.  The number of carbon atoms in mammalian sphingoid bases is 





, and shorter sphingoid bases, 14 carbon atoms, are prevalent in 
the fruit fly Drosophila memanogaster 
49
.  A systematic sphingoid base nomenclature has 
been proposed 
50
 in which d and t designate the presence of two )di) or three (tri) 
hydroxyls, respectively, and the number of carbon atoms and desaturation(s) in the 
sphingoid base are expressed as x:y.  A superscript indicates the first carbon atom of any 
double bond(s), thus, phytosphingosine is t18:0 and sphingosine (sphing-4-enine) is 
d18:1
4
 according to this system. 
 Metabolites of sphingoid bases include branched species (methyl group addition 
at n-1, n-2, and other positions), hydroxylated species at the 4- and 6-positions,1-
phosphorylated species 
37
, mono-, di-, and tri-N-methyl species, and N-acyl (14 to 30 or 
more carbon atoms) species.  Double bonds of the E-configuration (trans) at the 4-,  8-
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, and  4,8-, and other positions of sphinganine are the product of direct sphingoid base 
desaturation in yeast, but in mammals, desaturation of N-acyl sphinganine (also called 
dihydroceramide) is the predominant source of sphingosine-based SL‟s 
51
.  Free long 
chain sphingoid bases (LCB‟s) are not typically abundant, for example, sub-micromolar 
concentrations have been detected in human glioma cells 
52
, however, sphingoid base 





Cleavage of sphingoid base phosphates at the carbon 2,3-position by sphingosine 
phosphate lyase eliminates the defining SL moiety, and remains the only known exit of 
SL from their metabolic pathway 
56
. 
Dihydroceramide and Ceramide 
The terms dihydroceramide and ceramide connote classes of N-acyl sphinganine 
and N-acyl sphingosine molecular species, respectively, where fatty acid alkyl chains of 
C16 to C24 [or greater than C30 in dermal tissues 
57
] are amide linked to the amino group 
of the sphingoid base.  This N-acyl chain variety derives from the acyl-CoA substrate 
specificity of six known human (dihydro)ceramide synthase isoforms 
58, 59
, for which the 
systematic names CerS1 to CerS6 have been proposed 
60
.  Dihydroceramide can be 4,5-
E-desaturated to produce ceramide 
61
, or 4-hydroxylated by 4-dihydroceramide 
desaturase 2 to produce phytoceramide in mammalian cells 
46
.  Hydroxylation and 
desaturation at other positions have also been reported 
62
. 
 Functional group addition at the 1-hydroxy position of dihydroceramide or 
ceramide provides another level of structural diversity.  Headgroups may be primarily 
linked by phosphodiester bonds at the 1-hydroxyl position yielding sphingomyelin 
(ceramide-1-phosphocholine, SM), ceramide phosphoethanolamine (CPE), and ceramide 
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phosphoinositiols).  Ceramide may also be 1-O modified via phosphorylation or acylation 
to yield ceramide-1-phosphate 
63
 or 1-O-acyl ceramide 
64
, respectively.  One alternative 
to de novo biosynthesis for the generation of sphingoid bases is the De-N-acylation of 
dihydroceramide to produce sphinganine.  Likewise, de-N-acylation of ceramide and 
phytoceramide produces sphingosine and phytosphingosine, respectively.  These 
sphingoid bases are therefore derived from the "turnover" or "salvage" pathway, and are 




By far the most structurally diverse sphingolipids are the glycosphingolipids 
(GSLs).   Here the carbohydrate headgroup is O-linked to the 1-hydroxyl position 
yielding a monohexosylceramide, which may be either glucosylceramide (GlcCer) or 
galactosylceramide (GalCer).  Collectively called cerebrosides, these molecules serve as 
foundations for hundreds of unique molecular structures generated by the repeated 
glycosylation of a growing carbohydrate "tree" using different carbohydrate monomers 
(i.e. glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, fucose, N-
acetylneuraminic acid, etc.).  The GSL family may be subdivided into broad classes of 
neutral and acidic lipids based on the absence or presence of ionizable moieties such as a 
carboxylic acid or sulfate.  GSL may be further subdivided into the ganglio- (Gg), globo- 
(Gb), isoglobo- (iGb), lacto- (Lc), neolacto- (nLc), arthro- (At), and mollu- (Mu) series, 
each of which is defined by a unique tetrasaccharide core (Figure 1.2). 
7 
 
Root Name Abbreviation Core Structure
Ganglio Gg Gal 1-3GalNAc 1-4Gal 1-4Glc 1-1‟Cer
Lacto Lc Gal 1-3GalNAc 1-3Gal 1-4Glc 1-1‟Cer
Neolacto nLc Gal 1-4GalNAc 1-4Gal 1-4Glc 1-1‟Cer
Globo Gb GalNAc 1-3Gal 1-4Gal 1-4Glc 1-1‟Cer
Isoglobo iGb GalNAc 1-3Gal 1-3Gal 1-4Glc 1-1‟Cer
Mollu Mu GalNAc 1-2Man 1-3Man 1-4Glc 1-1‟Cer




















































Figure 1.2.  Glycosphingolipid nomenclature.  The core tetrasaccharide structures that 
define each GSL group are listed, and a portion of ganglioside biosynthesis is shown. 
 
 One nomenclature for GSL is the Svennerholm system 
68
 where G is used to 
denote ganglioside, and M, D, and T represent the number of sialic acid residues (mono-, 
8 
 
di-, and tri-sialyl GSL, respectively) and the relative position of the species after 
resolution by thin-layer chromatography (for example the relative migrations of the GM 
series are GM3 > GM2 > GM1).  Another more explicit nomenclature system sequentially 
lists saccharide subunits from the non-reducing end to the ceramide moiety, and specifies 
both the branching carbon atom linkage and the anomeric configurations of inter-
saccharide bonds.  For example, the core tetrasaccharide structure of ganglio-series GSL 
may be written Gal 1-3GalNAc 1-4Gal 1-4Glc 1-1'Ceramide, or simply Gg4Ceramide.  
Because some GSLs are isomeric (the same set of saccharide subunits but different 
anomeric linkages or different branching), this nomenclature system uses Roman 
numerals and Arabic superscripts to designate the root saccharide and its specific 
position(s), respectively, which are substituted, and abbreviates the core tetrasaccharide 




Neu5AcGg4Ceramide and its 




Neu5AcGg4Ceramide.  As an alternative to Roman 
numerals and Arabic superscripts, branch saccharides may be written in parentheses after 
the saccharide to which they are linked.  The multiple anomeric linkages between 
carbohydrate monomers and further carbohydrate modifications such as sulfation and 
acetylation increase the number of potential GSL structures beyond 1000, indicating 
considerable room for discovery and characterization. 
Lysosphingolipids  
Other types of sphingoid base derivatives have recently garnered a great deal of 
attention because they have been found to be highly bioactive 
69
.  These lipids include the 
1-phosphates and the “lyso” sphingolipids such as lyso sphingomyelin (sphingosyl-
phosphocholine) and psycosine (glucosylsphingosine).  Additionally, the N-methyl-
9 
 
derivatives (N-methylsphingosine, N,N-dimethylsphingosine, and N, N, N-
trimethylsphingosine) have also been observed 
70
, however, their route of synthesis and 
biological function have not been fully determined.  
Cellular Biology 
Sphingolipids are bioactive compounds that serve not only as components of 
biologic structures such as membranes and lipoproteins, but also as regulators of cell 
proliferation, differentiation, cell-cell and cell-matrix interactions, cell migration, 
intracellular (and extracellular) signaling, membrane trafficking, autophagy and cell 
death
2, 71, 72
.  For most of these functions, there is structural specificity with respect to the 
major sphingolipid subclass (for example, in many cases ceramides are growth inhibitory 
whereas sphingoid base 1-phosphates usually stimulate growth)
73
.  And within 
subclasses, changes as minor as the presence or absence of a double bond can have a 
major impact on function
74
.  Methodologies which have the ability to distinguish and 
quantitate many sphingolipids rapidly, such as LC-MS/MS, are particularly suited for 
elucidating sphingolipids that affect biochemical behavior. 
While sphingolipids are ubiquitous amongst eukaryotes, only some viruses 
prokaryotes contain sphingolipids
75
; however, general trends in sphingolipid structure 
exists in organisms of increasing evolutionary complexity.  For example, plants are 
characterized as having both phytosphingosine (t18:1) as well as a higher occurrence of 
sphingodienes (d18:2)
76-78
.  Yeast are characterized as having phytosphingosine as well 
as d20:1 and d20:0 sphingoid bases
79
.  Insects have been shown to have d14:1 and d14:0 
as their primary sphingoid bases
49, 80
.  Insects have also been shown to have high 





 Mammals have been shown to have mainly d18:1 and d18:0 sphingoid bases; 




.    
Sphingolipid biosynthesis and turnover take place in several organelles and 
cellular compartments.  The committed step in sphingolipids biosynthesis is the 
condensation of a plamitoyl-CoA and a serine by serine palmitoyl transferase to form 3-
keto-sphinganine, which is rapidly reduced to sphinganine by 3-keto-sphinganine 
reductase.  Sphinganine can then be acylated by a number of (dihydro)ceramide 
synthases (discussed later).  Dihydroceramides can then be desturated by 
dihydroceramide desaturases which leads to ceramide formation on the cytosolic surface 
of the endoplasmic reticulum
85
.  Ceramides are then transfered to the Golgi by either 
vesicular
86
 or non-vesicular transport, the latter mediated by ceramide transfer protein 
(CERT)
87
.  The Golgi is the major site for the biosynthesis of complex sphingolipids such 
as glucosylceramide and sphingomyelin, except for galactosylceramide, which is made 
on the lumen side of the ER after ceramide is transfered inside by a flipase.  The complex 
sphingolipids products are then transferred to the plasma membrane by vesicular 
transport.  Turnover of sphingolipids takes place mainly in lysosomes
88
; however, some 
degradation takes place in the plasma membrane, such as sphingomyelinases
89
.  
Sphingolipids are degraded into sphingoid bases in the lysosome, which are then released 
to the cytosol where they can be phosporylated to sphingoid base 1-phosphates by 
sphingosine kinase or recycled back into the ER for use by ceramide synthases.  
Sphingoid base 1-phosphates can also be cleaved into ethanolamine phosphate and 
hexadecenal or hexadecanal (d18:1 and d:18:0 bases respectively) by sphingosine 
phosphate lyase in order to remove sphingolipids from the pathway.   
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Classical Methods of Sphingolipid Analysis 
Thin Layer Chromatography (TLC) 







 and more complex GSLs 
93
.  Advances in 
high performance TLC (HPTLC) have allowed improved resolution of some molecular 
species 
94, 95
.  However, TLC does not offer sufficient structural specificity to guarantee 
homogeneity within a single spot.   
High Performance Liquid Chromatography (HPLC)  
HPLC has also been employed for separation and identification of derivatized and 
underivatized sphingoid bases 
96-98





, and monohexosylceramides 
101
.  HPLC has the advantage of being 
relatively inexpensive while providing resolution of SL‟s based on headgroup (normal 
phase) or N-acyl chain length (reverse phase).  Detection of SL‟s has been primarily 
performed by UV or fluorescence after deacylation (for complex SL‟s) and modification 
of the free amine via addition of a chromophore such as ortho-phthaldehyde 
102
.  
However, recent advances in evaporative light-scattering detection (ELSD) 
103
 avoid any 
necessity for derivatization.  Ceramides or other complex SL can also be analyzed either 
by O-benzylation derivatization using benzoyl chloride 
104, 105
 or benzoic anhydride 
106
 or 
by synthetic derivatives (such as short chain analogues with 7-nitro-2-1,3-benzoxadiazol-
4-yl (NBD) moieties 
107, 108
.  However, accurate quantitation often depends on definitive 
resolution of SL species, which HPLC alone cannot guarantee.  This disadvantage 





Immunochemistry techniques have yielded information on sphingolipids such as 
GD3
109
 and ceramides 
110
.  These methods typically employ antibody affinities for 
isolation of SL‟s for quantitation or standard protein isolations through gel 
electrophoresis coupled to blotting.  However, these methods do not have a guaranteed 
high level of specificity, because the antibody may have affinity for the desired target as 
well as undesired targets.  Certainly protein work is valuable for understanding the 
expression of regulatory enzymes and their precursor genes; however, these studies prove 
much more valuable when coupled to more rigorous quantitative analysis on the species 
in the sphingolipid biosynthetic and regulatory pathways.   
Sphingolipid Analysis via Mass Spectrometry 
Electron Ionization (EI) Mass Spectrometry  
Ions are produced in EI by the interaction of analytes and electrons in the gas 
phase.  Electrons are produced by heating a wire, which has a current running through it.  
Electron ionization mass spectrometry was initially used to elucidate the structures of 
ceramides 
111, 112
 and neutral GSL species 
113, 114
.  These early experiments permitted the 
analysis of SL‟s as intact molecular species, and yielded diagnostic fragmentations that 
could distinguish isomeric SL structures 
115, 116
.  Because these molecules were either 
relatively large or polar they required derivatization of the SL to trimethylsialyl 
117
 or 
permethyl ethers to reduce their polarity and increase their volatility for efficient transfer 
to the gas phase.  However, in some cases observation of intact higher mass molecular 
ions was precluded because EI induced extensive fragmentation owing to its relatively 
high-energy imparted during ionization.  Additionally, resolution of complex mixtures of 
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SL‟s with varying headgroups, sphingoid bases, and N-acyl combinations was 
particularly challenging using these methods as resulting spectra displayed multiple 
fragments from multiple precursors. 
Fast Atom Bombardment (FAB) and Liquid Secondary Ionization Mass 
Spectrometry (LSIMS) 
 FAB and LSIMS are techniques for the ionization of non-volatile lipids in which 
SL‟s are ionized off a probe tip by collisions with a beam of either accelerated atoms or 
ions 
78, 118-120
.  FAB and LSIMS are considered to be much “softer” ionization techniques 
than EI as they ionize lipids directly without need for derivatization and yield intact 
molecular ions with a lesser degree of fragmentation.  These ionization techniques 
allowed analysis of complex mixtures of monohexosylceramides 
121





 as individual molecular species could be distinguished by mass. 
Structural information could also be obtained from mass spectrometric analysis, 
especially if tandem mass spectrometric analyses were employed to select an ion of 
interest, collisionally dissociate it, and detect the resultant product ions.  When either (M 
+ H)
+
 or (M – H)
-
 precursor ions fragment, they do so at specific positions to yield 
product ions distinctive for the structural sections of SL: headgroup, sphingoid base, and  
N-acyl fatty acid 
124
.  These pathways of fragmentation can be influenced by the 
inclusion of alkali metal ions as (M + Metal)
+














FAB and LSIMS have some limitations for SL analysis.  Both of these methods 
require a matrix to solubilize the analyte of interest and aid in its ionization.  These 
matrices induce a significant amount of background chemical noise, which can limit 
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sensitivity, especially for lower molecular mass species, such as the free sphingoid bases.  
Methods such as Dynamic FAB 
126, 127
 partially solved this problem with continuous 
application of solvent and matrix to the probe tip; however, the ~ 100-fold reduction in 
background noise was not enough to completely eliminate background chemical noise 
from matrix at low analyte concentrations. 
Electrospray Ionization   
Electrospray ionization (ESI) allows SL‟s in solution to be continuously infused 
directly into the ion source of a mass spectrometer 
128-130
.  The central component of this 
ion source is a hollow metal needle, which is held at a high positive or negative potential.  
At the ending tip of the needle, highly charged solvent droplets containing SL‟s are 
formed and are subsequently drawn into the orifice of the mass spectrometer via both a 
potential and atmospheric pressure difference.  During transition from atmospheric 
pressure to vacuum the solvent is pumped away and the analyte of interest is ionized in 
the gas phase.  This ionization technique results in a much softer ionization, and when 
optimized yields primarily intact ions with little or no fragmentation. 
 Early ESI ion sources required low flow rates and multiple pumping stages to 
remove excess solvent.  However, ESI provided greatly reduced chemical noise and 
yielded sensitivity orders of magnitude lower than either FAB or LSIMS.  Structural 
information could likewise be obtained via tandem mass spectrometry, whereby specific 





High Performance Liquid Chromatography Mass Spectrometry (HPLC-MS) and 
Tandem Mass Spectrometry (MS/MS)   
ESI‟s method of direct sample introduction and ionization via solution naturally 
lends itself to coupling HPLC prior to mass spectrometric analysis for added separation 
and analytical robustness for quantitation.  When analyzed in this manner SL‟s may be 
de-salted, chromatographically focused, and selectively eluted enhancing sensitivity.  
HPLC also serves to reduce the complexity of the eluent at any given elution time, which 
greatly reduces ionization suppression effects from other species further improving 
quantitative accuracy and sensitivity.  Additionally, HPLC allows the separation of 
isomeric and isobaric species, which are often indistinguishable by mass spectrometry 
alone.    
HPLC-MS/MS has been used to identify, quantify, and determine the structures of 
free sphingoid bases, free sphingoid base phosphates 
131-133
, ceramides, 
monohexosylceramides (both galactosylceramides and glucosylceramides), 
lactosylceramides, sphingomyelins 
134, 135
 and more complex glycosphingolipids 
136, 137
.  
Complete chromatographic resolution of all individual species is not required in LC-
MS/MS because the mass spectrometer is able to differentiate between many components 
present in a mixture by their mass and structure (for example, all of the N-acyl chain 
length variants of Cer).  Sphingolipidomic separations have mainly been distributed 
between two types of HPLC: reversed phase LC 
138, 139
 for separations based on the 
length and saturation of N-acyl chains (for example, to separate sphingosine and 
sphinganine) and normal phase LC 
138, 140
 to separate compounds primarily by their 
headgroup constituents (for example, resolving ceramide from sphingomyelin, etc.). The 
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requirement for some LC separations many not be immediately realized, for example, 
sphingosine and sphinganine have easily resolved precursor and product ions.  However, 
typically in biological samples sphingosine is much more abundant than sphinganine, and 
the (M + 2) isotope of sphingosine will have the same precursor m/z as sphinganine, and 
so will interfere with the quantitation of sphinganine unless the sphingoid bases have 
been separated by LC 
138
. 
Matrix Assisted Laser Desorption Ionization Mass Spectrometry and Tandem Mass 
Spectrometry   
Matrix assisted laser desorption ionization (MALDI) has been used to identify 
ceramide, monohexosylceramide, and sphingomyelin 
141
 as well as complex GSLs, 
including lactosylceramide and gangliosides 
142
.   Samples are prepared for MALDI by 
mixing a solution containing the analyte with a solution containing a matrix compound 
often in much greater concentration.  MALDI matrices are typically small substituted 
organic acids that contain a moiety that absorbs the photonic energy of the laser 
143
.  
Absorption of the laser energy causes the matrix to become vibrationally excited and 
volatilize taking analyte molecules with it into the gas-phase.  Here the analyte and 
matrix molecules under go charge exchange reactions and the analyte becomes ionized.  
Matrix choice is key to successful generation of intact molecular species with minimal 
fragmentation and has been thoroughly reviewed 
144
. 
MALDI ion sources are typically used in conjunction with time-of-flight (ToF) 
mass analyzers because the laser pulse and resulting ion plume provides a discreet event 
which is compatible with ToF mass analysis 
145
.  Because of the nature of MALDI 





MALDI efficiently produces singly charged ions, which in conjunction with the high m/z 
range of ToF instruments, has aided in the observation of higher molecular weight GSLs 
148
.  One downside to this ionization technique is that many matrices produce abundant 
background chemical noise at lower m/z values, which precludes analysis of smaller free 
sphingoid bases and similarly sized SLs.  However, new advances in matrix choices and 
high pressure sources may provide an opportunity to study these lower molecular weight 
SLs by MALDI. 
Sphingolipidomics 
In order to perform investigations on a biological scale, analyses must encompass 
a “sphingolipidomic” scale, for which mass spectrometry is the analytical tool of choice 
for several important reasons.  First, mass spectrometry provides a high level of 
specificity with regard to identification of complex molecular species via molecular mass.  
This is especially true with either high resolution and accurate mass measurement, which 
yields empirical formula 
147
, or tandem mass spectrometry (MS/MS) 
149
, which yields 
structural information.  Second, mass spectrometry provides levels of sensitivity that are 
orders of magnitude lower than that of classical techniques (sub fmol detection limits).  
This enables detection of SL‟s present in minute quantities (~ fmol or less) in small 
sample amounts (~10
6
 cells).  Third, the signal response of SL‟s analyzed by mass 
spectrometry can be correlated to their concentration yielding quantitative information.  
[It should be noted that accurate and precise quantitation via mass spectrometry requires 
use of appropriate internal standards to control for sample losses in extraction, and 
normalization for differences in ionization and fragmentation of various individual 
molecular species.]  Finally, mass spectrometry provides a wide dynamic range, typically 
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several orders of magnitude for quantitation of SL‟s.  This allows analysis of SL‟s which 
vary in abundance over this range in biological systems (i.e. sphingomyelin versus 
sphingosine-1-phosphate).  In spite of all these positive attributes, poor choices in 
analytical techniques and experimental design can yield erroneous results.  These include 
sample handling and extraction protocols, separation of isomeric and isobaric species 
prior to mass analysis, internal standards, ionization technique, instrument (mass 





Quantitative analysis of sphingolipids for lipidomics using a triple 
quadrupole mass spectrometer and a quadrupole linear ion trap mass 
spectrometer in the triple quadrupole mode 
 
Many methods have been used for sphingolipid analysis, from classic methods 
such as TLC 
150
 and HPLC 
151
, to mass spectrometry, which has proven to be useful for 
analysis of broad categories of sphingolipids from sphingoid bases and their 1-phosphates 
130, 131, 152, 153
 to ceramides (Cer) 
128, 131, 135, 154, 155
 and simple mono- and 
dihexosylceramides 
127, 138, 142, 156, 157
, sphingomyelins (SM) 
138, 158-161
, and more complex 
glycosphingolipids 
114, 137, 162-166
.   
Some of the methods are able to profile subspecies in multiple categories 
130, 131, 
138, 167-170
.  Chromatographic resolution of specific subsets of sphingolipid allows for 
focused analysis of each subset 
130, 138
.  These methods allow for quantitation through the 
use of internal standards, which are required to elute in a similar time window and follow 
similar fragmentations. 
For quantitation of sphingolipids it is essential to have internal standards that are 
valid for each of the subspecies that the method reports to quantify 
131, 169
.  These can be 
stable isotope, N-acyl chain length variants, or sphingoid base variants.  This study 
compares the validity of an internal standard cocktail that is commercially available and 
contains species to quantify sphingoid bases, sphingoid base 1-phosphates, and several 
families of complex sphingolipids. Short chain, d17:1 and d17:0, sphingoid bases and 
sphingoid base 1-phosphates are used for quantitation of the 18:1 and 18:0 species; 
whereas, complex species are quantified by comparison to C12:0 N-acyl species. 
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It is common in mass spectrometry to have various categories of instruments 
available for identification and quantitation of analytes, which involve using different 
combinations of modes of ionization and mass analyzers.  This dissertation describes the 
optimization and validation of a sphingolipid internal standard cocktail on both a triple 
quadrupole and a quadrupole linear-ion trap mass spectrometer operating in the triple 
quadrupole mode, both equipped with electrospray sources.  Because it is an intrinsic 
feature of mass spectrometry that ion yields tend to vary considerably among different 
compounds, source, methods, and instruments, an analysis that purports to be quantitative 
will not be conclusive unless the methods involved are validated.  By first optimizing the 
ionization and fragmentation conditions for a wide range of N-acyl chain length analytes 
as well as the internal standards used to quantify them on both instruments, LC-MS/MS 
methods could be developed for quantitative analysis.  
 By using syringe infusion analysis to characterize the sphingolipid profile of 
RAW264.7 cells, LC-MS/MS methods were adjusted to quantify the major sphingolipid 
species found to be present.  Internal standards were then evaluated for their ability to 
quantify the naturally occurring species in RAW264.7 cells. 
Materials and Methods 
Materials 
Synthetic internal standards were obtained from Avanti Polar Lipids (Alabaster, 
AL).  These standards were provided in sealed ampules at concentration dated and 
certified by Avanti polar lipids as an internal standard cocktail (named LM-6002) (d17:1 
So, d17:0 Sa, d17:1 sphingosine 1-phosphate (S1P), d17:0 sphinganine 1-phosphate 
(Sa1P), d18:1/C12:0 Cer, d18:1/C25:0 Cer, d18:1/C12:0 GlcCer, d18:1/C12:0 
lactosylceramide, d18:1/C12:0 ceramide 1-P and d18:1/C12:0 SM) by Avanti Polar 
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Lipids (Alabaster, AL).  The sulfatide internal standard (d18:1/C12:0 sulfatide) and 
d18:1/C12:0 galactosylceramide were obtained from Avanti Polar Lipids (Alabaster, AL) 
as an individual compounds.  For comparison additional internal standards were obtained 
from commercial providers as follows.  Sulfatides (d18:1/16:0 and d18:1/C18:0) were 
obtained from Matreya (Pleasant Gap, PA).  All other chain length sphingolipids were 
either obtained from Avanti Polar Lipids (Alabaster, AL), or commercially unavailable 
d18:0 sphingolipids were synthesized by bubbling hydrogen gas through solutions 
containing the d18:1 sphingolipid and 10% Pd on charcoal (Sigma St. Louis, MO).  All 
solvents used were HPLC grade.  Methanol (HPLC grade) VWR (Catalog # EM-
MX0475), acetonitrile (HPLC grade) VWR (Catalog # EM-AX0145), chloroform (HPLC 
grade) VWR (Catalog # EM-CX1058), hexanes (HPLC grade) VWR (Catalog # JT9304-
33), formic acid (ACS grade) VWR (Catalog # EM-FX0440-7), acetic acid (ACS grade) 
Fisher (Catalog # A38C-212).  VWR (West Chester, PA) and Fisher (Pittsburgh, PA). 
Cell Culture 
RAW264.7 is a macrophage-like cell line derived from tumors induced in male 
BALB/c mice by the Abelson murine leukemia virus.  Cells were obtained from ATCC 
laboratories (cat# TIB-71; lot# 3002360).  RAW264.7 cells were grown in 60-mm plastic 
culture dishes in DMEM supplemented with 10% FBS, 4 mM L-glutamine, and 4.5 g/L 
glucose. RAW264.7 cells were cultured at 37 C, 95% relative humidity, and 5% CO2 
with 1.5 g/L sodium bicarbonate, 100 U/mL penicillin, and 0.1 mg/mL streptomycin in 
ThermoForma Steri-cult CO2 incubators.  Cells were passaged at 80% confluence and 
seeded at 2.5 x 10
6
 cells in 5 mL of media.  Cells were never passaged more than 20 
times.   
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Extraction of cells 
RAW264.7 cells were washed twice with PBS to remove excess media, scraped 
from the dish using Nalgene cell scraper (Rochester, New York) and transferred by 
pipette into a 13 x 100 mm borosilicate tube with a Teflon-lined cap (VWR, West 
Chester, PA). Additions of 0.5 mL CH3OH  and 0.25 mL CHCl3, followed by internal 
standards (500 pmol) dissolved in 0.02 mL ethanol were added to the test tube then the 
extracts were dispersed using a Brinson 1510 ultra sonicator at room temperature for 30 
s, and incubated at 48 C overnight in a heating block.  After cooling, 75 µl of 1 M KOH 
in CH3OH was added, mixed briefly by sonication, and incubated in a shaking water bath 
for 2 h at 37 C.  A fraction of 0.4 mL was transferred to a new test tube and solvent was 
evaporated using a Savant AES2000 Automatic Environmental Speedvac.  The dried 
residue was reconstituted in LC-MS/MS mobile phase (identical A:B composition to 
initial chromatographic conditions) for sphingoid base and sphingoid base 1-phosphate 
analysis.  The remainder of the initial extract was neutralized with 3 µl of glacial acetic 
acid, and 3 ml 1:2 (v/v) of CHCl3/H2O was added.  Samples were mixed and then 
centrifuged.  The lower layer was removed by a Pasteur pipet, and transferred to a new 
tube.  The dried residue was reconstituted in LC-MS/MS mobile phase (identical A:B 
composition to initial chromatographic conditions) for complex sphingolipid analysis  
Instruments 
Two different LC-MS/MS systems were used for lipidomic analysis: a Perkin 
Elmer Series 200 MicroPump system coupled to a PE Sciex API 3000 triple quadrupole 
mass spectrometer (Applied Biosystems, Foster City, CA), and a Shimadzu LC-10 AD 
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VP binary pump system coupled to a Perkin Elmer Series 200 autoinjector coupled to an 
ABI 4000 QTrap (Applied Biosystems, Foster City, CA).  
Liquid Chromatographic Separation  
 Sphingoid Bases, Sphingoid Base 1-Phosphates, and Ceramide 1-Phosphates 
Free sphingoid bases, sphingoid base 1-phosphates and the Cer-1-P were 
separated by reverse phase HPLC using a binary solvent system and a Supelco 2.1 x 50 
mm Discovery C18 column (Sigma St. Louis, MO) at a flow rate of 1 mL/min.  Mobile 
phase A consisted of CH3OH/H2O/HCOOH (58:41:1) (v,v,v) with 5 mM ammonium 
formate.  Mobile phase B consisted of CH3OH/HCOOH (99:1) (v,v)  with 5 mM 
ammonium formate.  Prior to the injection, the column was equilibrated for 0.4 min with 
60:40 (A/B).  After sample injection (50 L), the analytes were eluted with 60:40 A/B for 
0.5 min, followed by a 1.8 min linear gradient to 100% B, which was held for 5.3 min 
and followed by a 0.5 min wash of the column with 60:40 A/B to re-equilibrate the 
column before the next run.  
Complex Sphingolipids 
The Cer, monohexosylceramides (HexCer), SM, sulfatide (ST), LacCer, and Cer-
1-P were separated by normal phase HPLC using a binary solvent system and a Supelco 
2.1 x 50 mm LC-NH2 column at a flow rate of 1.0 mL/min.  Mobile phase A consisted of 
CH3CN/CH3OH/HCOOH (97:2:1) (v,v,v) with 5 mM ammonium formate.  Mobile phase 
B consisted of CH3OH/H2O/HCOOH (89:6:5) (v,v,v) with 50 mM triethylammonium 
acetate. Prior to injection, the column was equilibrated for 1.0 min with 100% A.  After 
sample injection, analytes were eluted with 100% A for 3 min, followed by a 1.0 min 
linear gradient to 100% B, which was held for 3.0 min, and then followed by a 1.0 min 
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linear gradient to 100% A.  The column was then re-equilibrated at 100% A for 1.0 min. 
Glucosylceramide and Galactosylceramide   
Because glucosylceramide and galactosylceramide coelute by the above method, 
biological samples that contain both can be analyzed by a separate method.  Dried 
samples are re-dissolved in CH3CN/CH3OH/H3CCOOH (97:2:1) (v,v,v) with 5 mM 
ammonium acetate.  The LC-Si column (Supelco 2.1 x 250 mm LC-Si) is pre-
equilibrated with CH3CN/CH3OH/H3CCOOH (97:2:1) (v,v,v) with 5 mM ammonium 
acetate for 1.0 min at 1.5 mL per min, sample is injected, and the column is isocratically 
eluted for 8 min.  GlcCer elutes at 2.56 min and GalCer at 3.12 min using this isocratic 
normal phase system; however, column age and previous sample load can influence the 
retention times of HexCer‟s by this method.  Periodic retention time confirmation with 
internal standards allows the monitoring of column stability and subsequent 
effectiveness.   
Quantitative LC-MS/MS  
Ion source temperature varied between 300 and 500 °C depending on solvent 
composition and mass spectrometer.  Q3 was set to pass molecularly distinctive product 
ions. A multiple reaction monitoring (MRM) method was created by setting Q1 and Q3 
to pass the precursor and product ions of the most abundant sphingolipid molecular 
species and fragment ion.  In both instruments N2 was used to collisionally induce 
dissociations in Q2, which was offset from Q1 by 30-120 eV.  For example, for Cer, 
these transitions occur at m/z 538.7/264.4, 566.5/264.4, 594.6/264.4, 622.7/ 264.4, 
648.7/264.4, 650.7/264.4, which correspond to Cer with a d18:1 sphingoid base and 
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C16:0, C18:0, C20:0, C22:0, C24:1, and C24:0 N-acyl chain, respectively.  The dwell 
time was 25 ms for each transition.  
Infusion Experiments 
 Identification of ionization and fragmentation parameters for standards 
 Prior to running of standard curves on either instrument, each analyte was diluted 
to a concentration of 1 to 10 pmol/µL in CH3OH and infused into the ion source at a rate 
of 0.6 mL/h to optimize ionization and fragmentation conditions for each sphingolipid 
species.  Once the LC elution was optimized, this procedure was repeated for each 
analyte dissolved in the solvent mixture at the appropriate ratios in which they elute from 
the column.  This optimization allows for correction of ionization conditions, as might be 
anticipated due to the differences in mobile phase composition. 
 The optimization procedure was identical for each analyte.  Ionization conditions 
were first varied to produce the maximum signal with the mass spectrometer functioning 
in only MS mode.  In the QQQ these settings were declustering potential (DP) and 
focusing potential (FP), and in the QTrap the settings were DP and entrance potential 
(EP).  After the Q1 settings are determined, product ion spectra are taken across a range 
of collision energies (CE).  Structurally specific product ions are identified.  One 
structurally indicative product ion is then chosen for optimization.  Collision energies and 
collision cell exit potentials (CXP) are then varied to produce optimal signal for the 
product ion of choice.  With optimal settings determined, the precursor/product ion pairs 





 Survey of species in biological samples profile  
Cellular extracts are resuspended in 0.5 mL CH3OH and infused into the QTrap at 
a rate of 0.6 mL/h to determine sphingoid base and fatty acid combinations within the 
sample. Several different precursor scans are used to determine sphingolipid composition.  
Precursor ion scans of m/z 184.4 are indicative of SM.  Precursor scans of m/z 264.4 and 
266.4 are then performed over a wide range of collision energies (35-75 eV) and mass 
ranges to check for other classes of sphingolipids and the corresponding d18:1 and d18:0 
subspecies (Cer, HexCer, LacCer, etc).  Precursor ion scanning also allowed the 
evaluation of the N-acyl chain length distribution as well as presence of hydroxylation.  
Precursor scans of m/z 264.4 and 266.4 +/- n*(14) are used to identify the sphingoid base 
profile within samples that have different chain lengths.  Similarly, precursor scans of m/z 
262.4 and 262.4 +/- n*(14) are used to identify the presence of d18:2 species.  
Standard Curves 
 Unless shipped as a 1 mg sealed ampule, powder of each sphingolipid was placed 
in a decicator overnight to ensure that each weighed amount was a true dry weight.  Each 
analyte was dissolved in methanol in concentrated stocks of approximately 0.5 mg/mL.  
These were then serially diluted to 0.5 to 1000 pmol in 50 µL solvent.  Each 
concentration was run by LC-MS/MS in triplicate.  Identical samples were analyzed on 
both mass spectrometers. 
Evaluation of Sphingolipid Recovery 
The non-soluble material from cellular extracts was re-extracted three times using 
the above method, and each extract was analyzed by LC-MS/MS for sphingoid base and 
sphingoid base 1-phosphate analysis.  The upper layer from the final step of the cellular 
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extracts was re-extracted 3 times with1 ml CHCl3.  The dried residue was reconstituted in 
LC-MS/MS mobile phase for complex sphingolipid analysis.  
Thioglycollate Elicited Macrophages  
Thioglycollate elicited macrophages were produced by collaborators using the 
following Lipid Maps protocol (http://www.lipidmaps.org/protocols/PP0000001400.pdf).  
Samples were shipped dry and extracted by the above protocol. 
Results 
The goal of these experiments was to develop reverse phase (Figure 2.1) and 
normal phase (Figure2.2) LC-MS/MS methods for the quantitation of sphingolipids on 
both an API 3000 triple quadrupole (QQQ) and ABI 4000 quadrupole linear-ion trap 


















































































Figure 2.1. Reverse phase LC-MS/MS of sphingoid bases, base 1-phosphates, and 
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Figure 2.2. Normal phase LC-MS/MS total ion chromatogram of Cer, GlcCer, SM, 
LacCer, sulfatide, and Cer1P.  Internal standards A) and RAW264.7 cells with internal 




Initial Ion Characterization 
Syringe infusion was initially used to characterize sphingolipid ionization and 
fragmentation behavior on the QQQ and QTrap.  In the QQQ, d17:1 and d18:1 So doubly 
dehydrate to form fragment ions of m/z 250.3 and 264.4 respectively (Figure 2.3); 
whereas, in the QTrap the most abundant product ion is the single dehydration product 
ion of m/z 268.3 and 282.3 respectively. Both instruments displayed formation of a [M-
CH4O2]
+
 product ions for So and Sa m/z 252.2 and 254.2 respectively, which resulted 
from cleavage of the 1 carbon and the hydroxyl at that position as well as dehydration at 
the 3 position.  Sa species on the QTrap undergo a loss of C2H6NO to produce a primary 
product ion of m/z 60 (Figure 2.4).  Sphingoid base 1-phosphates fragment via cleavage 
of the phosphate group and dehydration at the 3 position on both instruments yielding 
fragment ions of m/z 264.4 and m/z 266.4 for d18:1 and d18:0 sphingoid bases, 
respectively 
169
.  A general fragmentation mechanim is proposed in Figure A2.1. 
Cer fragments via cleavage of the headgroup from the 1 position, dehydration at 
the 3 position, and cleavage of the N-acyl chain to either m/z 264.4 for d18:1 species or 
m/z 266.4 for d18:0 species (Figure 2.5)  Other product ions are observed in the CID 
spectrum of d18:1/C12:0 Cer, including a single dehydration at m/z 464.5, double 
dehydration at m/z 446.4, loss of CH4O2  at m/z 434.4, cleavage of the N-acyl chain and a 
single dehydration at m/z 282.2, and loss of CH4O2  along with cleavage of the N-acyl 

































































































































































































HexCer fragmented via cleavage of the hexode from the 1 position, dehydration at 
the 3 position, and cleavage of the N-acyl chain to either m/z 264.4 for d18:1 species or 
m/z 266.4 for d18:0 species (Figure 2.6).  Other product ions are observed in the CID 
spectrum of d18:1/C12:0: single dehydration at m/z 626.6, deglycosylation and cleavage 
of the N-acyl chain at m/z 300.4, deglycosylation along with cleavage of the N-acyl chain 
and a single dehydration at m/z 282.2, and deglycosylation followed loss of CH4O2  along 
with cleavage of the N-acyl chain and a dehydration at m/z 252.3. 
In positive ion mode, LacCer fragment by cleavage of the lactose from the 1 
position, dehydration at the 3 position, and cleavage of the N-acyl chain to form a 
product ion m/z 264.4 (m/z 266.4 for dihydrolactosylceramides) (Figure 2.7)  
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. cleavage 
of the N-acyl chain to either m/z 264.4 for d18:1 species or m/z 266.4 for d18:0 species 
(Figure 2.6).  Other product ions are observed in the CID spectrum of d18:1/C12:0: single 
dehydration at m/z 626.6, deglycosylation and cleavage of the N-acyl chain at m/z 300.4, 
deglycosylation along with cleavage of the N-acyl chain and a single dehydration at m/z 
282.2, and deglycosylation followed loss of CH4O2  along with cleavage of the N-acyl 
chain and a dehydration at m/z 252.3. 
SM fragment by cleavage and charge retention by the phosphocholine headgroup 
to produce abundant m/z 184.4 ions; however, a significantly less abundant structurally 
significant product ion can be observed at m/z 264.4, which corresponds to the previously 







































































































Figure 2.7. Product ion scan of d18:1/12:0 LacCer by QTrap. Positive ion mode 
























































 Cer1P fragment in positive ion mode to m/z 264.4 for d18:1 species; however, 
other product ions are observed. (Figure 2.9A) 
138
.  Other product ions observed are a 
single dehydration at m/z 544.4, -HPO3 at 482.2, phosphate loss at m/z 464.5, and 
phosphate loss with a dehydration at m/z 446.5.  Negative ion mode loss of a charged 
PO3
-
  at m/z 78.9 was the primary product ion (Figure 2.9B) 
172
.  Other negative mode 
product ions included dehydration at m/z 542.3, amide bond cleavage at m/z 378.2, amide 
bond cleavage and dehydration at m/z 360.2, and charged phosphate loss at m/z 97.0.   
Sulfatides fragmented in a similar manner in negative mode with charge retention 
of the sulfate group at m/z 96.9 (Figure 2.10) 
173
.  Other product ions were more 
structurally indicative, such as m/z 390.2, which represents the N-acyl fatty and portion of 
the sphingoid base or m/z 240.9, which represents the sulfated galactose. 
Unnatural d17 species were used as internal standards for sphingoid bases and 
sphingoid base 1-phosphates.  Similarly, unnatural C12:0 variants were used as internal 
standards for complex species.  These non-naturally occurring sphingolipids were chosen 
in place of stable isotope internal standards due to cost and lack of availability.  Because 
these internal standards very rarely were observed in biological samples, background 























































































Figure 2.9. Product ion scan of d18:1/C12:0 Cer1P.  A) Positive ion mode B) 















































































Figure 2.10. Product ion scan of d18:1/24:1 ST by QTrap.  
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Ion selection within RAW264.7 cells  
Prior to selecting MRM pairs for each cell type, the variation in fatty-acyl chain length 
needs to be determined, which allows the MRM transitions to be tailored for the major N-
acyl species within the sample.  This is initially accomplished by syringe infusion of one 
sample dissolved in 1 mL of CH3OH/HCOOH (99:1) (v,v)  with 5 mM ammonium 
formate.  Precursor ion scans of m/z 184.4, the structure specific fragmentation indicative 
of SM, were first performed because SM are typically abundant and are indicative of both 
d18:1 and d18:0 based species (Figure 2.11).  Given the relative abundance of SM to 
other complex sphingolipids, lower abundance variations in sphingoid base of N-acyl 
fatty acid (i.e. α-OH, diene, methylation, etc) would be more easily observed.  In RAW 
264.7 cells, the major N-acyl chain length SM are C16:0, C18:0, C20:0, C22:0, C24:1, 
C24:0, C26:1, and C26:0.  Precursor scans of m/z 264.4 and 266.4 were then performed 
over a wide range of collision energies (35-75 eV) and masses to check for other classes 
of sphingolipids and the corresponding subspecies (Cer, HexCer, LacCer, etc) and verify 
that no significant variance in major N-acyl chain lengths was observed (Figure 2.12). N-
acyl chain lengths chosen for observation in RAW264.4 cells were C16:0, C18:0, C20:0, 
C22:0, C24:1, and C24:0.  Analysis of sulfatides via precursor m/z 96.9 scans revealed 




















































































































Sphingoid bases and sphingoid base 1-phosphates 
All species showed a linear signal response from 0.5 to 1000 pmol on both on 
both the QQQ (Figure 2.13A) and QTrap (Figure 2.13B).  Sphingosine 1-phosphates 
were observed to have the highest signal response on both instruments; however the Sa1P 
had a similar signal response to sphingoid bases.  Signal response for all species on the 
QTrap were 3 to 4 orders of magnitude greater than the QQQ.  Signal response for d17 
and d18 species were similar for each pair; however, differences in signal response in 
S1P and Sa1P demonstrate the need for individual internal standards for saturated and 
unsaturated species.  
Odd chain (d17:1 and d17:0) sphingoid bases and sphingoid base 1-phosphates 
provided accurate quantitation as internal standards for d18:1 and d18:0 sphingoid bases 
and sphingoid base 1-phosphates because the background natural abundance of d17 
species is less than 2 pmol per million cells.  This fact in conjunction with both LC 
elution window and similar shifts between So and Sa species increased confidence in 
quantitative assignment.  Ionization and CID conditions for these species are summarized 
in Appendix A.  Internal standards and naturally occurring chain lengths were evaluated 
on both the QQQ (Figure 2.13A) and QTrap (Figure 2.13B).  Major differences in 
product ion abundances were observed between the QQQ and QTrap.  Increased collision 
energy in the QTrap made the double dehydration the major product ion; however, the 
overall signal was lower.  Sa and other saturated species had weaker signal on the QQQ 





























Figure 2.13. Signal response for sphingoid bases and sphingoid base 1-phosphates 





 Signal response from 0.5 to 1000 pmol of Cer (Figure 2.14A and 2.14B) and 
dihydroceramide (DHCer) (Figure 2.14C and 2.14D) species were plotted.  Ionization 
and CID conditions for Cer (as well as other complex species) are summarized in Tables 
A.3. and A.4.  Ion yield for DHCer on the QQQ were 6 to 8 times lower than their 
respective Cer as observed in figures 2.14A and 2.14C.  For example, the area under the 
peak at 100 pmol on column for C16:0 Cer is seven times greater than that of  C16:0 
DHCer.  Fragmentation on the QTrap did not reveal a similar relationship as shown in 
figure 2.14B and 2.14D, where signal response for DHCer subspecies is ~85% of the 
corresponding Cer subspecies.  Signal response for all DHCer and Cer species was linear 
from 0.5 to 1000 pmol on both instruments; however, signal response for Cer on the 
QTrap was 3 orders or magnitude higher than the QQQ.  Signal response for DHCer 
species were almost 4 orders of magnitude greater on the QTrap.  There were virtually no 
difference in signal response based on N-acyl chain length, and the majority of the 
difference between chain lengths can be accounted for by the shifts in isotopic abundance 
induced by the addition of carbons in longer chain species.   
Hexosylceramides 
Ion yield for dihydroglucosylceramides on the QQQ (Figure 2.15C) was ~7 times 
lower than their respective GlcCer (Figure 2.15A) (500 pmol of C16:0 GlcCer on column 
resulted in an area under the peak of 1.29e05, while C16:0 dihydroglucosylceramide 
resulted in an area under the peak of 1.74e04).  Signal for GlcCer was ~2 orders of 
magnitude higher on the QTrap (Figure 2.15B and 2.15D) than the QQQ (500 pmol of 







































Figure 2.14. Signal response for varying N-acyl chain length Cer on the A) API 3000 
triple quadrupole and B) ABI 4000 quadrupole linear-ion trap mass spectrometer 
and dihydroceramides on the C) API 3000 triple quadrupole and D) ABI 4000 




































Log (fmol GlcCer on column)  
Figure 2.15. Signal response for varying N-acyl chain length GlcCer on the A) API 
3000 triple quadrupole and B) ABI 4000 quadrupole linear-ion trap mass 
spectrometer and dihydroglucosylceramides on the C) API 3000 triple quadrupole 
and D) ABI 4000 quadrupole linear-ion trap mass spectrometer.  
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while C12:0 GlcCer resulted in an area under the peak of 2.64e07).  All N-acyl chain 
lengths were linear over the range of 0.5 to 1000 pmol) on both instruments.  Saturated 
species had a lower signal response on the QTrap as well, although N-acyl chain length 
did not significantly impact signal response on either instrument.   
Sphingomyelins 
 Signal response for SM on the QTrap (Figure 2.16B) was only an order of 
magnitude higher than observed for the QQQ (Figure 2.16A) (3.42e8 versus 2.91e07 for 
500 pmol on column of C16:0 SM on the QTrap and QQQ, respectively).  
Dihydrosphingomyelin had similar signal response to SM on both the QQQ (Figure 
2.16C) and QTrap (Figure 2.16D).  N-acyl chain length did not significantly impact the 
signal response on either instrument. 
Lactosylceramides 
N-acyl chain length did not significantly impact ionization on either instrument, and 
signal response was linear for each species from 0.5 to 1000 pmol on column.  Signal 
response for LacCer (Figure 2.17A and 2.17B) is the lowest of the sphingolipids 
observed in positive ion mode.  This lower signal response is caused by increase in the B 
mobile phase, which contains TEAA.  While a decrease in solvent hydrophobicity is 
required to elute the LacCer, the TEAA component reduces ionization efficiency of the 
LacCer.  Analyzing LacCer on the QTrap improved signal by an order of magnitude with 
signal response for 500 pmol of C16:0 LacCer on column being 1.78e05 on the QTrap 
and 1.48e04 on the QQQ.  Dihydrolactosylceramides were 5 fold lower than LacCer on 
the QQQ; however, signal response for dihydrolactosylceramides on the QTrap were only 




 Neither N-acyl chain length nor saturation significantly affected signal response, 
which was linear from 0.5 to 1000 pmol on column for both instruments.  Reverse phase 
separation (Figure 2.1) with positive mode ionization allows separation of varied Cer1P 
by chain length as well as production of a structurally specific product ion (m/z 264.4).  
As with other sphingolipids, an increase in N-acyl chain length increased the collision 
energy required to optimize formation of the N” ions (Table A3-4). 
 Normal phase separation with negative mode ionization provides an orthogonal 
method for comparison with the reverse phase positive ion mode data.  Here chain length 
variants (Figure 2.2B) elute at virtually the same chromatographic time as the internal 
standard (Figure 2.2A).  In negative ion mode, Cer1P fragment by cleavage of the C1-O1 
bond to yield PO3
-




.  While this product ion is not 
structurally indicative, it is extremely abundant and allowed for sub-pmol detection limits 
(Figure 2.18).  Signal response for 100 pmol on column of C16:0 Cer1-P by normal 
phase was 7.15e06 on the QTrap and 2.52e5 by reverse phase.  Signal response was over 


































Log (fmol SM on column)  
Figure 2.16. Signal response for varying N-acyl chain length SM on the A) API 3000 
triple quadrupole and B) ABI 4000 quadrupole linear-ion trap mass spectrometer 
and dihydrosphingomyelin on the C) API 3000 triple quadrupole and D) ABI 4000 
quadrupole linear-ion trap mass spectrometer.  



























Figure 2.17. Signal response for varying N-acyl chain length LacCer and DHLacCer 
























Figure 2.18. Signal response for varying N-acyl chain length Cer1P and DHCer1P 







 Sulfatide species yielded significant signal in negative ion mode because 
sulfatides fragment via cleavage of C1-O1 bond to yield HSO4
-
 and charge retention by 
the sulfate 
174
.  The negatively charged sulfate product ion is highly abundant and allows 
for fmol detection limits. However, this product ion does not differentiate fatty acid and 
sphingoid base combinations.  The much less abundant fatty acid fragment ion (i.e. m/z 
390.2 in Figure 2.10) slowed for structural characterization at a higher limit of detection.  
Ionization conditions were identical for all sulfatide species (Table A3-A4).  Signal 
response for sulfatides on the QTrap (Figure 2.19B) was approximately an order of 
magnitude higher than the QQQ (Figure 2.19A) (signal response for 500 pmol of C16:0 
sulfatide on column was 1.18e07 for the QQQ versus 8.17e07 for the QTrap).  Neither N-
acyl chain length nor saturation significantly affected signal response, which was linear 























   
 
     Figure 2.19. Signal response for varying N-acyl chain le length Cer1P on the A) 




Recovery of sphingolipids and internal standards from RAW 264.7 cell extracts 
 To validate the extraction protocol, ~ 3.0 x 10
6 
RAW 264.7 cells (N=6) were 
spiked with internal standards and extracted.  Both the aqueous and organic layers were 
subjected to repeated re-extraction.  For long chain bases and their 1-phosphates greater 
than 90% of the total signal was recovered in the initial extraction, 5-8% in the second 
extraction and ~1% in the third (Figure 2.20).  The same percentages were recovered for 
the internal standard as for the endogenous analyte (Figure 2.20).  The presence or 
absence of the Δ4 double bond had no effect on recovery as d17:1 and d17:0 species were 
recovered similarly (427 ± 21 pmol for d17:1 and 413 ± 11 pmol for d17:0).   
The complex sphingolipid extraction had approximately 80% of the total 
extracted complex sphingolipids in the initial extract with the first and second re-
extractions containing approximately 15% and 5%, respectively (Figure 2.21).  N-acyl 
chain length distribution of the analytes did not vary between washes, so the relative 
ratios of analyte N-acyl chain length molecular species were not altered by the extraction 
















































Figure 2.20. Recovery of sphingoid bases and their 1-phosphates during cell 
extraction.  RAW264.7 cells were spiked with 500 pmol of internal standards and 
extracted four times, and recoveries were analyzed using LC-MS/MS on an ABI 4000 
quadrupole linear-ion trap mass spectrometer.  Samples were analyzed as an N=6 and 








































Figure 2.21. Recovery of complex sphingolipids during cell extraction.  RAW264.7 
cells were spiked with 500 pmol of internal standards and extracted four times and 
recoveries were analyzed using LC-MS/MS on an ABI 4000 quadrupole linear-ion trap 
mass spectrometer using a Supelco 2.1mm x 5 cm LC-NH2 column. Samples were 





Correction of signal for quantitation 
 Several factors were considered when quantifying molecular subspecies of 
sphingolipids, which included similarity in ionization and fragmentation behavior 
between analyte and internal standard, elution profile relative to internal standard, and 
potential internal standard background within biological samples.  Internal standards 
were used for each sphingoid base and sphingoid base 1-phosphate, which had shorter 
chain length variants (d17:1 and d17:0).  With complex sphingolipids, synthetic 
d18:1/C12:0 internal standards were used as a single standard for each family of complex 
sphingolipids.  These internal standards were structurally similar enough to endogenous 
species to both ionize and fragment at similar settings (i.e. a shift of 5 or less DP and FP 
and an ~ 2.5 eV difference in CE per addition of 2-4 CH2 to an N-acyl chain).  Both d17 
and C12 sphingolipids are typically thought of as very low abundance and unnatural 
species.  Choice of these unnatural chain length variants minimized the background of 
false internal standard signal within samples.  Shorter chain sphingoid bases and 
sphingoid base 1-phosphates maintained their chromatographic resolution between 
saturated and unsaturated species.  Complex analytes such as SM eluted in the same 
chromatographic window as their internal standard (Figure 2.2), which allowed for use of 
a single internal standard for each family of complex sphingolipid. Therefore, if there 
was any ionization suppression by interfering analytes, it is more likely to be uniform for 
all chain length subspecies including the internal standard.   
The areas under the peaks generated for both analytes and internal standards can 
then be integrated with mass spectrometer software (i.e. Analyst 1.4.2 for both Applied 
Biosystems instruments). Using identical integration settings (number of smoothes = 2-3, 
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bunching factor = 5-10, and noise threshold = 1 x 10
4
) to integrate both internal standard 
and analyte allowed quantitation using the formula (area unknown / area internal 
standard)*amount internal standard added.  Spiking the sample with internal standards 
prior to extraction serves as a control for extraction recovery.  Relative ionization and 
dissociation conditions between sphingoid base variants can also be corrected for by 
using standard curves for analytes, such as C12:0 Cer in figure 2.14A and C16:0 DHCer 
in 2.14B, if a known discrepancy exists between internal standard and analyte (such as 
the 8x difference in signal between Cer and DHCer on the QQQ).  Analytes can also be 
corrected for slight differences in isotopic abundance resulting from differences in 
chemical formula, most notably extra carbons from longer N-acyl chains.  The difference 
between C12:0 and C24:0 N-acyl chains is 12 additional carbon atmos, which contributes 
~13 % to a higher relative abundance of the (M+H+1)
+  
peak.  This lost signal can be 
factored back in by calculation of the differences in isotope abundance.  This is 







internal standards and analytes (larger molecules such as longer N-acyl chain length 




ratios than shorter N-acyl 
chain length variants).  These ratios are then converted to a total percent and the signal 
observed for the analyte is divided by the percent for its (M+H)
+
 and multiplied for the 
typically higher (M+H)
+
 percent from the internal standard.    
Sphingolipid Amounts in RAW264.7 cells and Thioglycollate Elicited Macrophages 
 Recovery of sphingolipids from extracts of RAW264.7 can be viewed [Table 2.1-
2.2] as well as explored in depth at www.lipidmaps.org.  Discussion of the following data 
represents the ability of these methodologies to detect and quantify sphingolipid amounts 
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across a timecourse (RAW264.7 0 and 24 h) as well as between different cell lines and 
treatments (RAW264.7 cells vs. thioglycolate elicited macrophages).  All data represents 
an N =3-4 and were integrated and quantitated according to the above described 
methodologies. 
 So varied between 31.7 and 48.2 pmol/µg DNA, while Sa was an order of 
magnitude lower and varied between 3.9 and 2.6 pmol/µg DNA.  Sphingoid base 1-
phosphates followed a similar trend with So1P varying between 10.0 and 16.8 pmol/µg 
DNA, and Sa1P varying between 0.7 and 1.3 pmol/µg DNA.  TGEM samples had 
significantly lower abundances of So, So1P, and Sa1P (39%, 11%, and 8% relative to 
RAW264.7 0 h respectively), while Sa was 79% of the RAW264.7 0 h time point. 
 Complex sphingolipids were more abundant than the sphingoid bases and the 
sphingoid base 1-phosphates.  The data revealed that N-acyl chain length profiles of Cer 
and SM were similar with C16:0, C24:0, and C24:1 as the major N-acyl species.  GlcCer 
had a higher percentage of C22:0 relative to other complex sphingolipids; however, 
C16:0 and C24:0 were still major species.  Cer1P had C16:0, C18:0, and C24:1 as the 
two major species.  Quantitation of Cer and HexCer revealed that only minor variations 
were calculated between RAW264.7 at both 0 and 24 h and TGEM samples.  The one 
exception was d18:1/C24:0 Cer in RAW264.7 cells at 0 and 24h (decrease from 12.3 to 
5.3 pmol/µg DNA from 0 to 24 h).  In RAW264.7 cells SM was the most abundant 
complex sphingolipid, having 15 times more total SM than total Cer (539.5 and 37.1 
pmol/µg DNA respectively).  TGEM had a higher abundance of SM relative to 
RAW264.7 cells at 0 h with individual increases in N-acyl chain length for 23% (C18:0) 
to 53% (C24:1).  TGEM samples displayed a notably different Cer1P N-acyl profile than 
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Table 2.1.  Quantitation of sphingoid bases and sphingoid base 1-phosphates from 
RAW264.7 cells cultured for 24 h and thioglycolate elicited macrophages. 
      












RAW264.7    0 h  38.8 ± 4.2   3.9 ± 1.0 10.0 ± 2.1 1.3 ± 0.2 
RAW264.7  24 h  48.2 ± 4.4   2.6 ± 0.6 16.8 ± 1.8 0.7 ± 0.1 








Table 2.2.  Quantitation of complex sphingolipids from RAW264.7 cells cultured for 





















Cer       
RAW 0 h 12.1 ± 4.2 0.6 ± 0.1 0.4 ± 0.1 3.9 ± 0.3 7.8 ± 0.7 12.3 ± 1.0 
RAW 24 h 9.2 ± 1.4   0.4 ± 0.1 0.2 ± 0.0 2.1 ± 0.5 6.3 ± 1.3   5.3 ± 1.4 
TGEM 0 h 10.0 ± 1.0 0.8 ± 0.3 0.5 ± 0.1 4.6 ± 1.6 6.1 ± 1.2 10.4 ± 0.4 
       
HexCer       
RAW 0 h 7.8 ± 0.9 0.6 ± 0.1 0.5 ± 0.1 7.1 ± 0.6 2.6 ± 0.3   5.1 ± 0.8 
RAW 24 h 8.4 ± 0.5 0.4 ± 0.1 0.4 ± 0.0 4.1 ± 0.2 2.9 ± 0.2   4.4 ± 0.2 
TGEM 0 h 7.9 ± 2.9 0.3 ± 0.1 0.2 ± 0.0 1.2 ± 0.3 3.2 ± 0.5   2.3 ± 0.4 
       
SM       
RAW 0 h 340.6 ± 30.7 17.9 ± 1.2 9.8 ± 0.8 28.1 ± 2.1 98.1 ± 7.0 45.0 ± 3.3 
RAW 24 h 359.3 ± 49.5 11.6 ± 1.7 6.3 ± 1.1 27.3 ± 5.6 120.9± 9.8 63.7 ± 8.4 
TGEM 0 h 456.0 ± 42.2 22.0 ± 2.8 11.6 ± 1.8 37.9 ± 7.7 150.1± 9.2 69.2 ± 9.3 
       
Cer1P       
RAW 0 h 104.7 ± 7.5   11.3 ± 1.0 2.3 ± 5.1 2.8 ± 1.5 56.0 ± 2.0   2.1 ± 0.3 
RAW 24 h 85.6 ± 6.8 6.4 ± 0.2 1.1 ± 1.3 2.1 ± 0.7 51.2 ± 8.6   2.8 ± 0.5 
TGEM 0 h 33.4 ± 5.4 23.6 ± 1.5 2.0 ± 0.2 10.0 ± 1.0 18.0 ± 6.4   7.3 ± 0.6 
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RAW264.7, although quantities of Cer1P in TGEM samples were only 53% of Cer1P in 
RAW264.7 cells at 0 h.  C16:0 Cer1P was 58% of total Cer1P in RAW264.7 cells at 0 h; 
whereas, C16:0 Cer1P was on 35% of total Cer1P in TGEM samples.  However, the 
percent of C18:0 Cer1P relative to total Cer1P was elevated in TGEM samples versus 
RAW264.7 cells at 0 h(25% and 6% respectively). 
Discussion 
  Because of the structural complexity of sphingolipids, mass spectrometry has 
been used for decades to identify individual species.  Concurrently application of these 
techniques to quantitative analysis has also been explored 
138, 175, 176
.  These developments 
have driven a need in the sphingolipid community for not only high quality internal 
standards, but also validation that these internal standards are applicable to quantitation 
of naturally occurring sphingolipids.  Verification requires exploration of ionization and 
fragmentation conditions of both internal standards and the analytes they are supposed to 
represent.  Fortunately, most fragmentation mechanisms of sphingolipids arise via 
cleavage of the amide bond (removal of N-acyl fatty acid) and do not vary with the length 
of the fatty acid cleaved (other than requiring increasing collision energy with increasing 
chain length).  This behavior allows use of synthetic non-natural chain length species, 
which are significantly less cost prohibitive than stable-isotope labeled internal standards 
for each individual molecular species.  Evaluation of these methodologies across a range 
of possible mass spectrometers and manufacturers provides for identification of 
differences in ionization, fragmentation, and mass analyzers 
177
. 
Coupling liquid chromatography to mass spectrometric analysis has many 
advantages.  LC can be used for de-salting of the compounds of interest in biological 
64 
 
samples as well as providing a mechanism to focus the sample in a small volume via 
column retention and elution.  LC also has the ability to separate isomers that might not 
be distinguished by MS or MS/MS alone 
178, 179
.  LC also reduces the ionization 
suppression typically observed in infusion experiments 
180
 by reducing the complexity of 
the eluent at any given elution time 
181
 as coeluting analytes having greatly different gas 
phase basicity or acidity can suppress the ionization of one or the other.  
To validate internal standards for quantitation of a biological experiment, first one 
must know the range of fatty acid and sphingoid base combinations in the cell or tissue 
type in order to verify that internal standard choice allows quantitation of all observable 
species.  This is accomplished by precursor ion scans of the structure specific fragments 
indicative of the various classes of sphingolipids.  SM are typically looked for first via 
precursor m/z 184.4 scans (positive mode cleavage of charged phosphocholine 
headgroup) because they are abundant and often indicate the presence of both So and Sa 
based species. For example, in RAW 264.7 cells, the major N-acyl chain length SM were 
C16:0, C18:0, C24:0 and C24:1, which comprised 93% of total SM.  Following the SM 
analysis, other classes of sphingolipids may be identified using a structure-specific 
precursor ion scan of m/z 264.4, which corresponds to doubly dehydrated d18:1 
sphingoid bases 
130
.  Likewise classes of dihydrosphingolipids, which lack the Δ4 double 
bond, can be identified via precursor scans for 266.4 
130, 131, 181
.  Other complex 
sphingolipid variants can be detected with modifications to the precursor ion scan m/z 
value based on the presence of absence of additional double bonds, oxidation, increasing 
or decreasing chain length, or other alterations.  For example precursor ion scan of m/z 





.  Precursor ion scan of m/z 208.4 and 210.4 can detect d14:1 and d14:0 based 
species, such as the ones found in insects 
49
.  These precursor scan will also detect the α-
hydroxy fatty acid species 
182
 and N-acyl chain length variants.  However, a single 
collision energy will not produce optimized signal over a large range, so spectra will not 
necessarily be indicative of relative amounts of sphingolipids.  Once the combination of 
sphingoid bases and N-acyl variants within a system are determined, the corresponding 
transitions should be incorporated into a MRM method to allow quantitation of all 
identified species (assuming suitable internal standards are available).  
After data is collected, post-processing must be done to account for any potential 





 isotopes are very common and must be considered 
153
 as potential 
contributors of false signal. For example, So and Sa only differ by 2 Da (a single double 
bond).  So species are usually much more abundant; therefore, the [M+H+2]
+
 signal from 
So-based species, will lead to increased signal for Sa-based species.  Reverse phase LC 
resolves this problem in sphingoid base and sphingoid base 1-phosphates if the species 
are baseline resolved chromatographically as in Figure 2.1.  However, normal phase 
separations do not always offer baseline resolution of So and Sa-based species 
138
.  In 
these cases, the So-based species are integrated first and the theoretical [M+H+2]
+
 
abundances are calculated.  The calculated [M+H+2]
+
 values are then subtracted from the 
integrated signal observed for Sa-based sphingolipids.  This method allows the accurate 
quantitation of dihydrosphingolipids.  
By optimizing ionization and dissociation conditions for a wide range of N-acyl 
chain lengths (C12:0 to C24:0) of each subspecies such as Cer, corrections can be made 
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to account for decreases in signal response associated with an increase in N-acyl chain 
length.  Previously, these corrections were applied to syringe infusion relative to internal 
standards 
128, 183
.  The LC-MS/MS methods described, allow for reduction in the amount 
of species observed in a given chromatographic period (reduction in MRM cycle time) as 
well as insuring identical conditions for MRM analysis of analytes and internal standards.  
In summary, these methods provide a template to analyze sphingolipids on either a triple 
quadrupole or quadrupole linear-ion trap mass spectrometer.  Applying a similar template 
for other similar instruments will allow optimization for accurate, precise, and 





SIMPLE: Sphingolipid isotopic metabolic precursor labeling 
experiments using U-[
13
C] palmitate to estimate de novo sphingolipid 
biosynthesis and turnover 
 
Recently LC-MS/MS methods 
37, 52, 130, 138
 have been developed to quantify sphingolipids.  
Quantitative studies of sphingolipids provide some insight into cellular mechanisms such 
as apoptosis; however, many mechanisms could be more fully elucidated by distinction 
between biosynthesis and turnover 
184-187
.  
Analysis of stable isotope incorporation into sphingolipids by mass spectrometry 
has been explored previously 
188-190
; however, here several advantages versus these 
previous methods are discussed.  In this method uniformly-labeled [
13
C]-palmitate is used 
to distinguish between pre-existing sphingolipids and de novo biosynthesized 
sphingolipids. Labeled palmitate was chosen because it can be incorporated into the 
pathway at two points: initially by serine palmitoyltransferase 
191, 192
, which catalyzes the 
condensation of serine and palmitoyl-CoA to form 3-keto-sphinganine, and later by one 
of several (dihydro)ceramide synthase isoforms 
41, 59, 193
.  This treatment produces labeled 
and unlabeled d18:0 and d18:1 sphingoid bases (sphinganine and sphingosine 
respectively), as well as four sets of complex sphingolipid species.  These may be 
completely unlabeled, labeled in only their sphingoid base, labeled in only their N-acyl 
fatty acid, or labeled in both their sphingoid base and N-acyl fatty acid.  MS and MS/MS 
analysis distinguishes both the number and the position of label incorporation. Here mass 
shifts in precursor and product ion pair m/z values by either 16 or 32 Da reveal whether 
the label is present in either the sphingoid base, N-acyl fatty acid, or both.  
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The utility of this sphingolipid isotope metabolic precursor labeling (SIMPLE) 
method is demonstrated by the quantitation of sphingolipids in HEK293 and RAW264.7 
cells treated with U-
13
C-palmitate.  Coupling SIMPLE with quantitation of labeled and 
unlabeled precursor fatty acyl-CoA pools allows correction of labeled sphingolipid values 
based on isotopic enrichment (i.e. specific activity) of the precursor pool.     
Materials and Methods 
Materials 
The internal standards as defined in chapter two were obtained from Avanti Polar 
Lipids (Alabaster, AL).  U-[
13
C]-palmitate (98%) was purchased from Cambridge Isotope 
(Andover, MA).  Phospholipase D (Streptomyces chromofuscus) was purchased from 
Biomol (Plymouth Meeting, PA).  Fumonisin B1 was obtained from Matreya (Pleasant 
Gap, PA).  All solvents were HPLC grade.  The HEK293 cells (ATCC # CRL-1573) 
were obtained from the ATCC (Manassas, VA).  Tissue culture dishes were obtained 
from VWR (Buffalo Grove, IL).  Fetal bovine serum was supplied by Hyclone (Logan, 
Utah). 
Cell Culture 
 HEK293 cells were grown in 60-mm plastic culture dishes in DMEM F12 (50:50 
v/v) media with 10% fetal calf serum in ThermoForma Steri-cult CO2 incubators with 5% 
CO2 and 90% relative humidity at 37°C.  In labeling experiments cells were incubated 
with 0.1 mM U-
13
C-palmitate in a 1:1 molar complex with fatty acid-free bovine serum 
albumin.  In experiments involving FB1, an ethanol stock of FB1 was added to the cell 




Extraction of cells 
Cells were extracted for sphingolipids analysis as defined in chapter 2. 
Phospholipase D Treatment 
  1000 units of Phospholipase D (Streptomyces chromofuscus) were suspended in 
0.1 ml of 3 mM decylglucopyranoside (Sigma) and 100mM Tris HCl (pH 8.0).  An 
aliquot of the complex fraction was treated with PLaseD and incubated for 15 min at 
37 C in a heating block.  Samples were then dried under vacuum in a Savant AES2000 
Automatic Environmental Speedvac and reconstituted in LC-MS/MS mobile phase for 
analysis. 
Liquid Chromatography Electrospray Tandem Mass Spectrometry of Sphingolipids 
All sphingolipids data was collected by LC-MS/MS as defined in chapter 2.  
Cell extraction for Fatty acyl-CoA Determination 
The medium was aspirated from dishes of adherent HEK293 cells, which were 
then washed twice with ice-cold PBS.  Cells were scraped up in 1 mL PBS using a Nalge 
Nunc cell scraper (Rochester, New York) and transferred by pipette into 13 X 100 mm 
borosilicate screw cap test tubes using 0.5 ml CH3OH.  Cells were extracted by a 
modified Folch procedure. Internal standard (10 L of 50 pmol/ L 15:0-CoA in CH3OH) 
was added, followed by sonication using a Brinson 1510 ultra sonicator three times for 30 
s each. An additional 250 L of CHCl3 was added, and sonicated for 30 sec. The extract 
was placed in a 50  C heating block for 30 min and then cooled to room temperature. 
CHCl3 (250 L) was added and vortexed for one minute, then 250 L H2O was added 
and vortexed for 1 min. After centrifugation (2500 rpm, 5 min), the upper (aqueous) layer 
was carefully removed with a Pasteur pipet and transferred into an HPLC vial. A quantity 
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of CH3OH was added to the extract to increase its volume by 10% of the initial extract, 
which increased the solubility of very long-chain acyl-CoA (22 to 26 carbon atoms) in 
the extract. 
Liquid Chromatography Electrospray Tandem Mass Spectrometry of Fatty acyl-
CoA Species 
 Fatty acyl CoAs were separated by reverse phase HPLC using a Shimadzu SCL-
10A VP system controller, two LC-10AD VP pumps, DGU-14A degassing unit, and a 
Perkin-Elmer Series 200 autosampler. The column was an XTerra 2.1 x 30 mm MS C18 
column with 2.5 m particles used at a flow rate of 0.2 mL/min.  Mobile phase A 
consisted of CH3OH/H2O (70:30) (v,v)  with 10 mM triethylammonium acetate [TEAA].  
Mobile phase B consisted of CH3OH/CH3(CH2)2CH2OH (90:10) (v,v) with 10 mM 
TEAA. The pump program was as follows: 100% A for 1.5 min to equilibrate column at 
100%A, 10 µL injection, 100% A for 1.7 min, gradient to 100% B at 6.3 min, hold 100% 
B until 11.3 min, gradient to 100% A at 11.4 min, 100% A at 14.5 min.  
An Applied Biosystems MDS Sciex 4000 QTrap triple quadrupole/linear ion trap 
instrument was used in positive ion mode with the Turbo V ESI source and N2 was used 
for the nebulizing gas, desolvation, curtain, and collision gases. Fatty acyl-CoA precursor 
ions were (M + H)
+
 species. Multiple reaction monitoring (MRM) methods selected (M + 
H)
+
 precursor ions with Q1 and structure-specific product ions with Q3 (neutral loss of 
507 Da).  
 Acyl-CoA standards (Avanti Polar Lipids, Inc., Alabaster AL) in 0.5 mg aliquots 
were dissolved in 1.0 mL CH3OH up to arachidoyl-CoA and in 1.0 mL 
CH3OH/CH3(CH2)2CH2OH/CHCl3 for behenoyl-CoA and longer. After dilution to 10 
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pmol/ L, each standard was infused at 5 L/min and compound-dependent parameters 
(desolvation potential [DP], collision energy [CE], and collision-activated dissociation 
[CAD] gas) were optimized. Flow injection analysis (FIA) of individual fatty acyl-CoAs 
was used to optimize source-dependent parameters (curtain gas, needle voltage, 
temperature, nebulizing gas, and desolvation gas).  
Results 
Mass spectrometry method development 
Sphingolipids undergo structure specific fragmentation upon tandem mass 
spectrometry that allows analysis of large numbers of subspecies, including both 
biosynthetic (i.e. sphingomyelin and glucosylceramide) and signaling species (i.e. 
sphingoid base 1-phosphates 
138
) and fragment as shown in chapter 2.  Incorporation of 
U-
13




















SM, however, fragments much differently.  Here the charge resides on the 
phosphocholine headgroup resulting in a product ion of m/z 184.4.  Therefore, while the 
total carbon number can be known for a SM molecular species by the precursor m/z, the 
exact nature of the backbone sphingoid base and fatty acid cannot be inferred unless 

































Analysis of the acyl-CoA profile in HEK293 cells treated with 0.1 mM U-
13
C-
palmitate revealed that 55% of 16:0-CoA was labeled by 6 h and that the labeled 
palmitate CoA thioesters were both elongated and desaturated (Figure 3.2).  The 
incorporation was rapid for 16:0-CoA (35% by 1 h), but elongated 18:0-CoA, and 
desaturated (16:1-CoA and 18:1-CoA) species showed a slower rate of incorporation.  
Both 18:0-CoA and 18:1-CoA appeared to reach a steady-state by 3 h at 19% and 8% 
respectively.  Both 16:0-CoA and 16:1-CoA appeared to still be increasing after 6 h.  The 
sphingolipid profile in extracts of HEK293 cells treated with 0.1 mM U-
13
C-palmitate 
was first explored by precursor ion scans of highly abundant SM (m/z 184.4), which 
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allowed determination of possible sphingoid base and fatty acid combinations (Figure 
3.3).   
To verify these backbone and fatty acid combinations, precursor ion scans were 
performed for m/z 264.4 (d18:1) and m/z 266.4 (d18:0) to detect the corresponding free 
unlabeled sphingoid bases, Cer, and HexCer.  Major N-acyl chain lengths in HEK293 
cells were C16:0, C18:0,C 20:0, C22:0, C24:1, C24:0,C 26:1, and C26:0 with d18:1 and 
d18:0 sphingoid base backbones.  The presence of elongated U-
13
C-palmitate in N-acyl 






































Figure 3.2. Fatty acyl-CoA species in HEK293 cells treated with 0.1 mM U-
13
C-
palmitate for 0 to 6 h. 
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Figure 3.3. Positive mode precursor ion scan of extracts of HEK293 cells treated 






Time points were taken over 6 h at 1 h intervals.  A distribution of chain lengths is 
observed in the unlabeled [
12
C]-Cer (Figure 3.4).  The major Cer, d18:1/16:0 Cer, 
decreases from 100 ± 20 to 50 ± 10 pmol/mg protein from t=0 to 1 h, while amounts level 
off by 3 h at 30 ± 5 pmol/mg protein.  Other chain lengths of unlabeled Cer produced 
similar patterns.  Decrease in d18:1/24:1 Cer was observed from 50 ± 10 to 40 ± 10 
pmol/mg protein from 0 to 1 h, and the quantity stabilized at 20 ± 5 pmol/mg protein by 3 
h.  Total unlabeled Cer decreased from 250 ± 70 to 110 ± 20 pmol/mg protein.  
d18:1/20:0, d18:1/26:1, and d18:1/26:0 were minor species each being present at < 3 
pmol/mg protein.  Unlabeled Cer that was d18:1/24:0 decreased from 60 ± 10 to 40 ± 10 
pmol/mg protein from 0 to 3 h and remained at that level until 6 h.  Unlabeled Cer that 
was d18:1/16:0 and d18:1/24:0 Cer decreased by the largest percentage over 6 h.  
d18:1/24:1 Cer decreased the most to 20 ± 10 pmol/mg protein at 6h from the initial 60 ± 
10 pmol/mg protein.  d18:1/16:0 Cer levels had decreased at 6 h to 40 ± 10 pmol/mg 
protein from the initial 100 ± 20 pmol/mg protein.   
Alteration in N-acyl chain length distribution over the time course was observed 
in unlabeled [
12
C]-Cer.  The d18:1/16:0 Cer decreased from 39% of total unlabeled [
12
C]-
Cer to 33% by 6 h; likewise, d18:1/24:0 Cer declined from 24% to 17% by 6 h.  The 
percent lost was seen as an increase in d18:1/16:0 Cer, d18:1/18:0 Cer, and d18:1/22:0 
Cer, which increased from 1% to 3%, 8% to 14%, and 7% to 9% respectively.  
d18:1/24:1 Cer remained constant at 20% over all time points. d18:1/20:0, d18:1/26:1, 







C] ceramides from extracts of HEK293 cells treated with 
0.1mM [
13
C]-palmitate for 0 to 6 h.  
 
   U-[
13
C]-palmitate was shown to be readily incorporated into sphingolipids in 
HEK293 cells.  Incorporation into the N-acyl chains was examined and designated as the 




Figure 3.5. Fatty acid labeled ceramides from extracts of HEK293 cells treated with 
0.1mM [
13
C]-palmitate for 0 to 6 h.  
 











C]-16:0  Cer showed incorporation of 20 pmol/mg protein ± 5 
pmol by 1 h, then amounts increased by 1.5 pmol/(mg protein*h) for a final concentration 
of 28 ± 6 pmol/ mg protein at 6h.  d18:1/[
13
C]-18:0 Cer amounts were above the limit of 
detection at 1 h, but did not reach amounts greater than 3 pmol/mg protein until the 3 h 

















C]-24:1 Cer were greater than the limit of detection by 
















C]-26:0 Cer were not above the limit of detection by 6 h.  Chain length 









C]-18:0 Cer, which remained at 84% and 10% respectively.  All other chain 
lengths of fatty acid labeled Cer were less than 2% total signal even when above the limit 
of detection.   
Complex sphingolipids having incorporated label into both the fatty acid and 
sphingoid base were quantitatively the predominant labeled species.  Incorporation into 









C]-18:0 Cer were the major labeled species 




C]-16:0 Cer increased from an initial quantity of 25 ± 5 
pmol/mg protein at 1 h to 50 ± 10 pmol/mg protein at 6 h.  This increase represents a 




C]-16:0 Cer of 5 pmol/(mg protein*h) from 1 h to 6 h 





C]-18:0 Cer had a value at 1 h  of 3 ± 1 pmol/mg protein, but did not 




C]-22:0 Cer reached 3 













C]-24:0 were also observed 





Figure 3.6. Dual labeled ceramides from extracts of HEK293 cells treated with 0.1 
mM [
13






C]-16:0 Cer was 82 ± 1 % of total dual-labeled ceramide for time 




C]-18:0 Cer remained between 8% and 9% of total 




C]-22:0 was 4% for all time points as 





C]-24:0 which reached 3% by 5h. 
Incorporation of U-[
13
C]-palmitate into the sphingoid base, but not the fatty acid, 
in Cer over 6 h was 5 ± 1 pmol/mg protein or less; however, a trend of increasing 
quantity can be observed (Figure 3.7).  Percentages of total Cer with label only in the 
sphingoid base backbone were maintained within ± 2 percent for all species with values 
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C]-d18:1/24:1 Cer respectively.      
 
Figure 3.7. Base labeled ceramides from extracts of HEK293 cells treated with 0.1 
mM [
13
C]-palmitate for 0 to 6 h.  
 
  
Phospholipase D Treatment 
 Incorporation of stable isotope label into Cer1P was not observed until after 
incorporation into SM; therefore, background levels of base and fatty acid labeled Cer1P 
were low.  Total background quantities in 1 x 10
6
 cells for HEK293 have consistently 
been less than 50 pmol.  Therefore conversion of SM to Cer1P via phopholipase D 
treatmentwould allow elucidation of FA/LCB combinations. 
81 
 
 Cells were grown in media containing 0.1 mM U-
13
C-palmitate were analyzed for 
background singly labeled Cer1P.  The total background concentration of singly-labeled 
Cer1P was 5 ± 2pmol/mg protein for both fatty acid and base labeled species.    Total 
singly labeled SM was 690 ± 20 pmol/mg protein in extracts prior to phospholipase D 
treatment.  After treatment with PLaseD, 70 ± 10 pmol/mg protein sphingoid base labeled 
Cer1P was observed along with 560 ± 20 pmol/mg protein of fatty acid labeled Cer1P.  
These summed to a total of 630 ± 20 pmol/mg protein, which represents a 91% recovery 









C]-24:1 being the most abundant chain lengths 
(Figure 3.8). 
 
Figure 3.8. Determination of label position in singly labeled sphingomyelins was 







Incorporation of label into HEK 293 cells   
Tables 3.1-3.3 show all the quantified sphingolipid species from HEK293 cells 
cultured for 3 h in media containing 0.1 mM U-
13
C-palmitate.  Quantitation was achieved 
by comparison of each peak within the sample to that of its appropriate internal standard.  
Base and fatty acid labeled SM were distinguished using PLaseD treatment.  
Incorporation of label into sphingosine-based species is rapid.  The immediate product of 
serine palmitoyltransferase, 3-keto-sphinganine was quickly metabolized as evidenced by 
3-keto-sphinganine amounts of < 10 pmol/mg protein.  Likewise the incorporation of 
label into dihydroceramide is observed, but dihydroceramide is apparently quickly 
desaturated to ceramide, as evidenced by low dihydroglucosylceramide labeled amounts; 
however some labeled dihydrosphingomyelin is observed. 
  Differential rates of labeled palmitate incorporation into complex sphingolipids 
were observed between GlcCer and SM.  While only 46% of total Cer was unlabeled at 3 
h, total unlabeled GlcCer and SM were 85% and 93% respectively.  SM made up the 
quantitative majority of the complex sphingolipids; however, label incorporation into SM 
by 3 h was low. 
So and Sa also displayed different proportions of labeling.  While the cells had a 
higher absolute concentration of So and So1P, Sa and Sa1P had greater relative 
incorporation of [
13
C]-palmitate (Table 3.3).  Of the 110 pmol/mg protein of So only 6 % 
was 
13








Table 3.1. LC-MS/MS quantitation of complex sphingolipids with a sphingosine 
base in HEK293 cells treated with 0.1 mM U-[
13
C]-palmitate for 3 h.  
 
Sphingolipid C16:0  C18:0 C20:0  C22:0  C24:1 C24:0 
 













   [
12
C] t = 0 100 ± 20    20 ± 5       <10     20 ± 5    50 ± 10    60 ± 10 
   [
12
C] t = 3 230 ± 10  120 ± 10       <10     30 ± 10     90 ± 10    40 ± 10 
   [
13
C] FA  50 ± 10    40 ± 10       <10      <10        <10        <10 
   Dual [
13
C] 150 ± 60    20 ± 10       <10      10 ± 0        <10    20 ± 10 
   [
13
C] Base  70 ± 10    50 ± 10       <10     20 ± 10     20 ± 10    40 ± 10 
       
GlcCer  
1230 ± 30  220 ± 10        <10   860 ± 40   210 ± 20   110 ± 20    [
12
C] t = 0 
    [12
C] t = 3 1560 ± 50  340 ± 30    20 ± 10   890 ± 10   230 ± 60   120 ± 30 
   [
13
C] FA 100 ± 30  20 ± 10    20 ± 10     30 ± 20     80 ± 10    50 ± 10 
   Dual [
13
C]   70 ± 10  30 ± 10    50 ± 10     20 ± 10     30 ± 10    80 ± 10 
   [
13
C] Base   20 ± 10  20 ± 10    40 ± 10     40 ± 10     80 ± 30    50 ± 20 
       
SM       
   [
12
C] t = 0   1870 ± 90  200 ± 20   240 ± 10     80 ± 20    400 ± 10  340 ± 50 
   [
 12
C] t = 3 1780 ± 100  270 ± 60    50 ± 70   140 ± 60  630 ± 260  240 ± 10 
   [
13
C] FA   130 ± 120   30 ± 60    50 ± 20     20 ± 10    30 ± 10   90 ± 20 
   Dual [
13
C]   250 ± 230   20 ± 30     60± 10     30 ± 10     20 ±10   60 ± 10 
   [
13









Table 3.2. LC-MS/MS quantitation of complex sphingolipids with a sphinganine 
base in HEK293 cells treated with 0.1 mM U-[
13
C]-palmitate for 3 h.  
 
 
Sphingolipid C16:0 DH  C18:0DH  C20:0 DH C22:0 DH  C24:1 DH C24:0 DH 
 













   [
12
C] t = 0     100 ± 30    10 ± 5       <10       <10    20 ± 10    10 ± 5 
   [
12
C] t = 3       90 ± 10   20 ± 10       <10       <10    40 ± 20    20 ± 10 
   [
13
C] FA           <10       <10       <10        <10        <10      <10 
   Dual [
13
C]      30 ± 10        <10       <10       <10    20 ± 10      <10 
   [
13
C] Base           <10        <10       <10        <10       <10      <10 
       
GlcCer             
   30 ± 10       <10       <10    150 ± 60    40 ± 20   [ 
12
C] t = 0          <10 
    [12
C] t = 3       60 ± 10    40 ± 10       <10       <10      70 ± 30    60 ± 30 
   [
13
C] FA           <10       <10       <10       <10      30 ± 10    20 ± 10 
   Dual [
13
C]       40 ± 10    80 ± 10       <10       <10    150 ± 20   110 ± 10 
   [
13
C] Base       70 ± 30        <10       <10       <10      20 ± 30       <10 
       
SM        
   [
12
C] t = 0  1150 ± 10   590 ± 20      <10     20 ± 10    230 ± 50   90 ± 30 
    
[
12
C] t = 3  1220 ± 80   680 ± 50    20 ± 10   120 ± 20    280 ± 70   70 ± 20 
   [
13
C FA]    270 ± 40   120 ± 30      <10     20 ± 10      60 ± 20   20 ± 10 
   Dual [
13
C]    310 ± 20     90 ± 20     10 ± 5     40 ± 10    110 ± 20     0 ± 10 
   [
13








Table 3.3. LC-MS/MS quantitation of long chain bases and their corresponding 
phosphates in HEK293 cells treated with 0.1 mM U-[
13





















C] t = 0   50 ± 10   10 ± 5    10 ± 5      <10 
[
12
C] 320 ± 40   22 ± 10  500 ± 20  30 ± 5 
[
13
C] 110 ± 20   17 ± 5  100 ± 20  60 ± 10 
 
Treatment with fumonisin B1 
 Exposure to FB1 caused a decrease in the quantity of labeled Cer.  Unlabeled Cer 
at 24 h were 46 ± 2 pmol/mg protein in control cells and 27 ± 1 pmol/mg protein in FB1 





C]-(fatty acid) Cer was 13 ± 1 pmol/mg protein but FB1 treated cells had only 3 ± 1 
pmol/mg protein base labeled Cer.  d18:1/[
12
C]-(fatty acid) Cer had a similar decrease 





C]-(fatty acid) Cer were 36 ± 1 pmol/mg protein for control cells 
and only 4 ± 1 pmol/mg protein in FB1 treated cells.  These relationships were also 
observed in SM and GlcCer.   
 Changes in sphingoid base quantities provide an explanation of cellular responses 




Figure 3.9. Sphingoid bases from HEK293 cells treated with 0.1 mM [
13
C]-palmitate 
± 50 uM FB1.  FB1 was added to the cells by supplement to the media for 6 h due to its 




C] origins were analyzed 






C]-Sa1P were below quantification limits in control cells; however, they 
were the major sphingoid base species in FB1 treated cells at 79 ± 12 pmol/mg protein 
and 450 ± 67 pmol/mg protein, respectively.  Unlabeled Sa and Sa1P were also observed 
to be 17 ± 4 pmol/mg protein and 88 ± 12 pmol/mg protein, respectively.  These values 
correspond to an 82% labeling of Sa and and 84% labeling of Sa1P.  This yields a 0.18 









Correction based on acyl-CoA pool  
Analysis of the fatty acyl-CoA profile in HEK293 cells treated with 0.1 mM U-
13
C-palmitate revealed that the 16:0-CoA was comprised of ~60% 
13
C-16:0-CoA labeled 
by 6 h.  One can also see that a portion of the 
13
C-16:0-CoA was both elongated and 
desaturated (Figure 3.2), with the 18:0-CoA species‟ specific activity reaching 25%, 
while 16:1-CoA and 18:1-CoA specific activities were 39 and 13 percent respectively, at 
6 h.   
Thus assuming this is a single precursor pool, the simplest prediction would be 
that in addition to the incorporation of U-
13
C-palmitate that is being synthesized into 
C16:0 Cer, there will also be incorporation of unlabelled precursor (
12
C-16:0-CoA). 
Therefore, for the first 3 hours, the total de novo incorporation of U-
13
C-palmitate in the 









C-16:0) labeled C16:0 Cer].  If the U-
13
C-palmitoyl-
CoA specific activity during this period is roughly estimated to be 30% (Figure 3.2), one 
would predict that Cer made de novo with 
12
C backbone could be (220/30)*100, or 733 
pmol/mg protein.  However, the change in 
12
C-C16:0 Cer from 0 until 3 h is only 130 + 
50 pmol/mg protein (
12
C-C16:0 Cer and fatty acid labeled C16:0 Cer).  
One cause of this could be the incorporation of Cer into the downstream products 
GlcCer and SM. The incorporation of U-
13
C-palmitate in C16:0 GlcCer at 3 h is 90 








C-16:0)].  If the U-
13
C-
palmitoyl-CoA specific activity during this period is roughly estimated to be 30%, a 
prediction of the amount of de novo 
12
C C16:0 GlcCer would be 210 pmol/mg protein. 
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However, the change in 
12
C-C16:0 GlcCer from 0 until 3 h is 330 + 100 pmol/mg protein 
(
12
C-C16:0 GlcCer and fatty acid labeled C16:0 GlcCer).   
The incorporation of U-
13









C-16:0)].  If the U-
13
C-palmitoyl-CoA 
specific activity during this period is roughly estimated to be 30%, a prediction of the 
amount of de novo 
12
C C16:0 SM would be 747 pmol/mg protein. However, the change 
in 
12
C-C16:0 SM from 0 until 3 h is 130- 40 pmol/mg protein (
12
C-C16:0 SM and fatty 
acid labeled C16:0 SM). 
Incorporation of label into RAW264.7 cells 
The sphingolipid profile in extracts of RAW264.7 cells treated with 0.1 mM U-
13
C-palmitate was first explored by precursor ion scans and the predominant N-acyl chain 
lengths for Cer, HexCer, SM, and Cer1P were identified as 16:0, 18:0, 20:0, 22:0, 24:1, 
24:0, 26:1, and 26:0.  The presence of elongated U-
13
C-palmitate in N-acyl chains was 
also detected.   
Time points were taken from 0 h to 24 h intervals with and without KDO2 lipid A 
treatment.  A distribution of chain lengths is observed in [
12
C]-Cer (Figure 3.10).  In 
control cells one major Cer, d18:1/16:0 Cer, increases from 0 h to 24 h at 3.9 ± 0.3 to 5.5 
± 0.1 pmol/µg DNA.   In treated cells one major Cer, d18:1/16:0 Cer, decreases from 8.5 
± 0.1 to 3.2 ± 0.1 pmol/µg DNA from t=0 to 2 h, then increases to 26.4 ± 0.2 pmol/µg 
DNA at 24 h.  In control cells a decrease in d18:0/24:1 Cer was observed from 13.1  ± 0.4 
to 4.3 ± 0.1 pmol/µg DNA from 0.5 to 24 h.  Treated cells followed a similar decrease 
until 8 h; however, an increase in d18:0/24:1 Cer was observed from 8.8  ± 0.3 to 15.0 ± 



















































C] ceramides from extracts of RAW264.7 cells treated with ± KDO2 
Lipid A and 0.1mM [
13
























































Figure 3.11. Fatty acid labeled ceramides from extracts of RAW264.7 cells treated 
with ± KDO2 Lipid A and 0.1mM [
13
C]-palmitate for 0-24 h.   
 
   U-[
13
C]-palmitate was shown to be readily incorporated into sphingolipids in 
RAW264.7 cells.  Incorporation into the N-acyl chains was examined and designated as 
the fatty acid labeled complex species in Cer (Figure 3.11), GlcCer, and SM. 












C]24:0 Cer in both treated and untreated cells.  Total fatty acid labeled Cer 
in treated cells continued to increase from 12 h to 24 h, while control decreased by 40 % 
between 12 h and 24 h.  This trend was consistent for all chain lengths.  In treated cells 
one major Cer, d18:1/16:0 Cer, increases from 1.2 ± 0.1 to 13.7 ± 0.1 pmol/µg DNA 
from t=0.5 to 24 h.  An increase in treated cells was observed for d18:0/24:0 Cer from 0.8  
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± 0.2 to 7.7 ± 0.3 pmol/µg DNA from 0.5 to 24 h.  Likewise, in treated cells, d18:1/22:0 
Cer increases from 0.4 ± 0.1 to 6.3 ± 0.1 pmol/µg DNA from 0.5 to 24 h. 
Cer having incorporated label into both the fatty acid and sphingoid base were 













C]-24:0 Cer were the major labeled species 





increased from an initial quantity of 4.4 ± 0.2 pmol/µg DNA at 0.5 h to 41.3 ± 1.3 





















































Figure 3.12. Dual labeled ceramides from extracts of RAW264.7 cells treated with ± 
KDO2 Lipid A and 0.1mM [
13
C]-palmitate for 0-24 h.   
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  In treated cells one major Cer, d18:1/16:0 Cer, increases from 1.2 ± 0.1 to 13.7 ± 0.1 
pmol/µg DNA from t=0.5 to 24 h.  An increase in treated cells was observed for 
d18:0/24:0 Cer from 0.8  ± 0.2 to 7.7 ± 0.3 pmol/µg DNA from 0.5 to 24 h.  Likewise, in 
treated cells, d18:1/22:0 Cer increases from 0.4 ± 0.1 to 6.3 ± 0.1 pmol/µg DNA from 0.5 
to 24 h.  Control cells showed an increase until 12 h, but then a decrease between 12 h 
and 24 h was observed.   
Incorporation of U-[
13
C]-palmitate into the sphingoid base, but not the fatty acid, 
in Cer showed a different chain length distribution than other labeled species.   (Figure 






















































Figure 3.13. Sphingoid Base labeled ceramides from extracts of RAW264.7 cells 
treated with ± KDO2 Lipid A and 0.1mM [
13






Described here is a sensitive and selective LC-MS/MS method utilizing a 
uniformly labeled [
13
C]-palmitate tracer for determination of the de novo biosynthesis of 
sphingolipids.  Utilizing an isotopic precursor was first addressed by Tserng et al., but 
this uniformly labeled precursor method has several distinct advantages over Tserng et al. 
use of a non-uniformly labeled precursor 
188
.  First, HPLC separation prior to introduction 
in the mass spectrometer allows the resolution of all N-acyl chain lengths of 
sphingolipids; whereas, the resolution of chain lengths longer than C16 by reverse phase 
GC is poor and could lead to miscalculation of chain length distribution 
188
.  Also Tserng 
et al. used repetitive scans as opposed to selected monitoring of precursor-product pairs 
with the explanation that other peaks of interest could be examined later.  If proper 
prescreening  with SM or Cer precursors scans is performed as described previously, then 
no scan time and resolution need to be lost to wide m/z windows.       
Fatty acid β-oxidation coupled with resynthesis could produce non-uniformly 
labeled [
13
C]-palmitate, and thereby skew data, as previously stated 
188
.  To examine this 
issue, precursor scans for m/z 184.4 and m/z 264.4 in treated HEK293 cells were 
performed.  The resulting data did not show significant quantities of labeled 
sphingolipids containing less than 16 amu shifts due to these β-oxidation pathways.  
Cer and GlcCer fragment to produce the same sphingoid base fragment ion of m/z 
264.4 as the sphingoid bases. SM fragments differently by keeping the charge on their 
phosphocholine moiety after dissociation.  Therefore, no charge is left on the Cer moiety 
to determine label position if the SM is singly-labeled.  In order to determine the label 
position in these singly-labeled SM, each extract is treated with PLaseD to convert the 
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SM to Cer1P.  The Cer1P will then fragment along the same pathways as Cer.  In a 
similar manner Tserng et al. used a sphingomyelinase to produce Cer from SM in HL60 
cells 
188, 189
.   
 The immediate product of SPT is 3-keto-sphinganine; however, no labeled 3-
keto-sphinganine (< 10 pmol) was detected.  HEK 293 cells have been screened for 3-
keto-sphinganine, and these values are consistently low (less than 5% the signal from Sa).  
This implies that 3-keto-sphinganine is rapidly reduced to Sa and does not accumulate 
under normal circumstances. 
 It has been previously shown that when cells are treated with FB1, production of 




C]-palmitate experiments independently 
confirm this conclusion and provide additional details regarding the fate of labeled Sa 
demonstrated by the accumulation of labeled Sa1P. 
Differences were observed in the relative quantities of the three types of labeled 
complex sphingolipids.  The dual-labeled species were the predominant species, and had 





C]-C16:0 Cer being the most abundant.  Singly-labeled Cer, 
however, were significantly different.  In the sphingoid base labeled Cer, [
13
C]-





C]-palmitate, which lowers the access of ceramide 
synthase to non-labeled fatty acids.  Conversely, fatty acid only labeled Cer had the 
opposite pattern, as d18:1/[
13
C]-16:0 was elevated.  GlcCer exhibited similar patterns to 
the Cer, but at lower concentrations.  SM was the major complex sphingolipid species 
observed.  However, fatty acidonly labeled and SM and sphingoid base labed SM initially 
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could not be distinguished from the MS/MS of the intact species, for previously 
mentioned reasons.  Furthermore, it is conclusively shown that de novo Cer biosynthesis 
is reduced by FB1 treatment due to the absence of U-[
13
C] labeled Cer.  The major 
increase in Cer population in FB1 treated cells was seen in the [
12
C] Cer species.  This 
increase is likely due to turnover of GlcCer and SM back to Cer.  
FB1 treatment induced a decrease in all labeled complex sphingolipids.  To 
explore the fate of the [
13
C]-palmitate in these samples, long chain base species were 
analyzed as well (Figure 3.9).  Treatment with FB1 induced an accumulation of de novo 
Sa; however, most of this [
13
C]-Sa is converted to [
13
C]-Sa1P.   This data suggests that 
HEK293 cells rapidly phosphorylate the accumulating de novo Sa, possibly to prevent 
apoptosis (30).  Conversion to Sa1P provides a mechanism not examined or discussed by 
Tserng et al (24) as a role of metabolism of pro-apoptotic So/Sa.   
Labeled Cer1P is produced in very low amounts in HEK293.  These values 
(typically fewer than 50 pmol/1x10
6
 cells) are subtracted from Cer1P amounts measured 
after PLaseD treatment, resulting in signal originating only from singly labeled SM (i.e. 7 
pmol/mg protein d18:1/[
13
C]-16:0 Cer1P prior to PLaseD treatment vs. 306 pmol/mg 
protein d18:1/[
13
C]-16:0 Cer1P after PLaseD treatment).  The derived individual amounts 
of sphingoid base and fatty acid only labeled sum to approximately 90% of the original 
SM, supporting the accuracy of this method‟s estimation of SM label position.  PLaseD 
readily converts the C12:0 SM internal standard to C12:0 Cer1P also at a rate of ~90%, 
which can then be used to quantify the other Cer1P produced.  This fact coupled with SM 
being observed in amounts significantly over detection limits (nmol range in 1 x 10^6 
cells) allow for an accurate recapitulation of singly-labeled SM.   
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 PLaseD treatment was able to distinguish labeled species in cells only treated for 
3 h with U-[
13
C]-palmitate (Table 3.1-3.3). Here the data show incorporation of label and 
when many of these tables from differing time points are examined together, a very 
detailed view of the pathway is observed.  
Use of U-[
13
C]-palmitate treatment aided in the identification of biosynthetic 
differences in RAW264.7 cells.  Most notably the increase in dual labeled Cer in treated 
cells.  The incorporation of label at two points demonstrates that this compound is indeed 
newly synthesized, and one can begin to hypothesize about KDO2 lipid A stimulated 
enzymes that would selectively produce the cual labled Cer in abundance. 
  U-[
13
C]-palmitate treatment in conjunction with ESI LC-MS/MS analyses yields 
highly informative data regarding sphingolipid mass.  It is also important to note that the 
biosynthetic pathways can be observed as seen with FB1 treatment with newly 
synthesized [
13





counterparts in control cells.  The observations would be less definitive without the 
distinctive positional labeling of complex sphingolipids produced by U-[
13
C]-palmitate, 





Development of additional mass spectrometric methods for specific 
applications 
 
 In the course of collaborations with other researchers, existing methods were 
adapted to analyze samples the use of existing methods with minor changes, such as the 
identification of a methylated species
198
, or significant changes, such as resolution of 
isomeric drug candidates and their metabolites
41
 have allowed for application-based 
discoveries.  Following are examples of successful collaborations and the methodological 
modifications that made them possible. 
A.  Safingol Toxicology After Oral Administration to TRAMP Mice: 
Demonstration of Safingol Uptake and Metabolism by N-Acylation and N-
Methylation 
            Pablo R. Morales;  Dirck L. Dillehay;  Steven J. Moody;  David C. Pallas;  Sarah     
            Pruett,  Jeremy C. Allegood;  Holly Symolon; Alfred H. Merrill Jr.  
            Drug and Chemical Toxicology, Volume 30, Issue 3 July 2007 , pages 197 – 216 
 
Abstract 
Safingol (L-threo-dihydrosphingosine) is an unnatural stereoisomer of sphinganine 
(D-Erythro-dihydrosphingosine) that is being tested as an anti-cancer agent. To learn how  
safingol affects a mouse strain that is often used in prostate cancer studies (Transgenic 
Adenocarcinoma of Mouse Prostate, TRAMP) mice, safingol was administered orally via 
supplementation of the diet at 0.0125, 0.025, 0.05 and 0.1% (w/w). Significant hepatotoxicity 
was found after 2 weeks at all dosages by analysis of liver alanine-aminotransferase (ALT); 
renal toxicity was only noted in mice administered 0.1% safingol, based on moderate 
elevation of blood urea nitrogen (BUN). Bilirubin, serum proteins, electrolytes and urinalysis 
were within normal limits. Hematology revealed a significant decrease in the packed cell 
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volume for the group fed at the higher dosage of safingol. Mice fed the 0.0125%  diet, 
maintained a normal weight during the experiment, but a significant weight loss (>30%) was 
observed in mice given the highest dosage of safingol. Tissues examined by histology  
showed moderate changes in liver for the 0.1% safingol group. Safingol added in the diet at 
these concentrations did not inhibit the production of prostate intraepithelial neoplasia (PIN), 
a common naturally occurring pre-neoplastic lesion in this strain of mice as they age. 
Analysis of safingol and metabolites in blood and tissues by liquid chromatography 
electrospray tandem mass spectrometry revealed extensive conversion of safingol to N-acyl-
species (analogous to the “ceramides” found in naturally occurring sphingolipids) and N- 
mono-, di-and tri-methyl metabolites. The latter are particularly intriguing because N, N- 
dimethylsphingosine is a highly toxic metabolite of sphingosine, therefore, some of these  
safingol metabolites may contribute its toxicity. 
Synthesis of methylated safingols 
 Internal standards were synthesized for mass spectrometric characterization and 
evaluation of LC mobility because a range of methylated sphingoid base standards were 
not available.  Methylsafingols were synthesized by methyl iodide addition to safingol as 
follows: 1.23 g of safingol (4.08 mmol) was placed in an Erlenmeyer flask, and the 
safingol was dissolved in 100 mL of ethanol.  With the addition of 3.4 mL of CH3I (54.90 
mmol) to the flask, the mixture was stirred at room temperature for three days.  Excess 
CH3I was precipitated by the addition of 500 mL ether.  The solvent was decanted to a 
round bottom flask and solvent was removed using a Heidolph Labrotora 4001 rotovap.  
Because the individual methylated species were difficult to separate from each other, the 
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mixture was evaluated by NMR and LC-MS/MS to determine the molar ratio between 
species and used as a mixture in experiments.  
 The presence of three separate methyl species was verified by LC-MS/MS, which 
yielded 3 individual peaks corresponding to the MRM transitions for N-methylsafingol,  
N,N-dimethylsafingol, and N,N,N-trimethylsafingol. 
13
C NMR was performed using a 
Varian Mercury Vx 300 MHz instrument.  A mixture of the methylated safingol was 
examined relative to TMS.  Three separate shifts were observed for the 
13
C from the N-
methyl carbons.  N-methylsafingol, N,N-dimethylsafingol, and N,N,N-trimethylsafingol 
were identified by signal at 34.5, 44.2, 52.8 ppm, respectively.  Integration of the signals 
for each of these subspecies allowed for determination of the molar ratios, which were 
approximately 1:0.5:0.1 for N-methylsafingol:N,N-dimethylsafingol:N,N,N-
trimethylsafingol, respectively. 
Liquid Chromatography Electrospray Tandem Mass Spectrometry of Sphingoid 
Bases and Safingol 
Free sphingoid bases (sphingosine, sphinganine, and safingol) as well as 
methylated, and acylated metabolites were separated by reverse phase HPLC using a 
binary system and a Supelco 2.1mm x 25 cm Discovery C18 column. Mobile phase A 
and B were the same as previously described for the sphingoid bases.  All runs were 
maintained at 0.5 mL/min flow rate.  Before each run, the column was equilibrated for 
1.5 min. at 60:40 (A:B). After sample injection (50 L by a Perkin Elmer Series 200 
Autosampler), the system was held at 60:40 (A:B) for 6.5 min, followed by a 9.0 min 
linear gradient to 100% B, which was held for 44.5 min and followed by a 1.5 min re-
equilibration at initial conditions.  
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Liquid chromatographic separation of safingol and sphinganine allowed 
distinction of these two species and their metabolites (Figure 4.1).  Safingol eluted with 
greater than 1 minute separation in standards and in biological samples  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
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Figure 4.1.  Reverse phase LC-MS/MS analysis of A) sphinganine, B) safingol, C) 
sphinganine and safingol in TRAMP mouse liver. 
 
As expected, safingol was N-acylated; however, there was also a significant amount of 
N-methylated species (mono-, di-, and tri-).  Both mono (Figure 4.2) and N,N-
dimethylsafingol (Figure 4.3) fragment via loss of the N-methyl groups and double 
dehydration to yield m/z 280 and 294.  Similar fragmentations were observed in pure 
mono and N,N-dimethylsphingosine purchased from Avanti Polar Lipids. 
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Figure 4.2. Product ion spectrum of N-methylsafingol (m/z 316.3). 
 



























Figure 4.3. Product ion spectrum of N,N-dimethylsafingol(m/z 330.3). 
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Trimethyl species (Figure 4.4) retain charge of the nitrogen and preferentially fragment to 
NH(CH3)3
+
 (m/z 60.1).  Methylated species eluted in identical order to sphingoid bases, 

























Figure 4.4. Product ion spectrum of N,N,N-trimethylsafingol. 
 
B. Upstream of growth and differentiation factor 1 (uog1), a mammalian 
homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-
stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-
independent manner in mammalian cells. 
            Venkataraman K, Riebeling C, Bodennec J, Riezman H, Allegood JC, Sullards    
            MC, Merrill AH Jr., Futerman AH. 





The longevity assurance gene (LAG1) and its homolog (LAC1) are required for acyl-
CoA-dependent synthesis of ceramides containing very long acyl chain (e.g. C26) fatty 
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acids in yeast, and a homolog of LAG1, ASC1, confers resistance in plants to fumonisin 
B(1), an inhibitor of ceramide synthesis. To understand further the mechanism of 
regulation of ceramide synthesis, we now characterize a mammalian homolog of LAG1, 
upstream of growth and differentiation factor-1 (uog1). cDNA clones of uog1 were 
obtained from expression sequence-tagged clones and sub-cloned into a mammalian 
expression vector. Transient transfection of human embryonic kidney 293T cells with 
uog1 followed by metabolic labeling with [4,5-(3)H]sphinganine or L-3-[(3)H]serine 
demonstrated that uog1 conferred fumonisin B(1) resistance with respect to the ability of 
the cells to continue to produce ceramide. Surprisingly, this ceramide was channeled into 
neutral glycosphingolipids but not into gangliosides. Electrospray tandem mass 
spectrometry confirmed the elevation in sphingolipids and revealed that the ceramides 
and neutral glycosphingolipids of uog1-transfected cells contain primarily stearic acid 
(C18), that this enrichment was further increased by FB(1), and that the amount of stearic 
acid in sphingomyelin was also increased. UOG1 was localized to the endoplasmic 
reticulum, demonstrating that the fatty acid selectivity and the fumonisin B(1) resistance 
are not due to a subcellular localization different from that found previously for ceramide 
synthase activity. Furthermore, in vitro assays of uog1-transfected cells demonstrated 
elevated ceramide synthase activity when stearoyl-CoA but not palmitoyl-CoA was used 
as substrate. We propose a role for UOG1 in regulating C18-ceramide (N-stearoyl-
sphinganine) synthesis, and we note that not only is this the first case of ceramide 
formation in mammalian cells with such a high degree of fatty acid specificity, but also 




C. Two mammalian longevity assurance gene (LAG1) family members, trh1 and 
trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA 
donors. 
            Riebeling C, Allegood JC, Wang E, Merrill AH Jr., Futerman AH. 
            J Biol Chem. 2003 Oct 31;278(44):43452-9. 
 
Abstract 
Overexpression of upstream of growth and differentiation factor 1 (uog1), a mammalian 
homolog of the yeast longevity assurance gene (LAG1), selectively induces the synthesis 
of stearoyl-containing sphingolipids in mammalian cells (Venkataraman, K., Riebeling, 
C., Bodennec, J., Riezman, H., Allegood, J. C., Sullards, M. C., Merrill, A. H. Jr., and 
Futerman, A. H. (2002) J. Biol. Chem. 277, 35642-35649). Gene data base analysis 
subsequently revealed a new subfamily of proteins containing the Lag1p motif, 
previously characterized as translocating chain-associating membrane (TRAM) protein 
homologs (TRH). We now report that two additional members of this family regulate the 
synthesis of (dihydro)ceramides with specific fatty acid(s) when overexpressed in human 
embryonic kidney 293T cells. TRH1 or TRH4-overexpression elevated 
[3H](dihydro)ceramide synthesis from l-[3-3H]serine and the increase was not blocked 
by the (dihydro)ceramide synthase inhibitor, fumonisin B1 (FB1). Analysis of 
sphingolipids by liquid chromatography-electrospray tandem mass spectrometry revealed 
that TRH4 overexpression elevated mainly palmitic acid-containing sphingolipids 
whereas TRH1 overexpression increased mainly stearic acid and arachidic acid, which in 
both cases were further elevated upon incubation with FB1. A similar fatty acid 
specificity was obtained upon analysis of (dihydro)ceramide synthase activity in vitro 
using various fatty acyl-CoA substrates, although in a FB1-sensitive manner. Moreover, 
in homogenates from TRH4-overexpressing cells, sphinganine, rather than sphingosine 
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was the preferred substrate, whereas no preference was seen in homogenates from TRH1-
overexpressing cells. These findings lend support to our hypothesis (Venkataraman, K., 
and Futerman, A. H. (2002) FEBS Lett. 528, 3-4) that Lag1p family members regulate 
(dihydro)ceramide synthases responsible for production of sphingolipids containing 
different fatty acids. 
Ceramide Synthase  
Sphingolipidomic analyses are important in that they reveal the pathways of 
metabolic flux of lipids from either biosynthesis or turnover in a biological system.  For 
example, a family of genes has recently been linked to the biosynthesis of ceramides and 
dihydroceramides in mammalian cells, and different gene products preferentially utilize 
different fatty acyl-CoA substrates 
58, 199, 200
.  Initially LASS1 (formerly named UOG-1) 
was investigated as a mammalian homolog to the yeast Longevity Assurance Gene 1 
(LAG-1) 
199
.  Detailed analysis of the full spectrum of N-acyl chain lengths for ceramides 
in HEK-293T transiently over-expressing LASS1 and monohexosylceramides revealed a 
marked increase in C18:0 Cer.   This matched in vitro assays which showed a preference 
for stearoyl-CoA (Figure 4.5), which in turn showed resistance to inhibition by fumonisin 




Figure 4.5. Ceramides in HEK-293T cells and HEK-293T cells transiently over-
expressing LASS1. 
  While radiolabeling experiments were also performed, the structure-specific data from 
LC-MS/MS analysis provided the necessary specificity to determine chain length 
preference for this protein.  
LASS4 and LASS5 (formerly trh1 and trh4) were subsequently shown also to 
determine chain length preference of DHCerS 
58
.  Analysis of N-acyl chain lengths from 
HEK-293T transiently over-expressing LASS4 or LASS5 is shown for C16:0 to C26:0 for 
ceramides (Figure 4.6), monohexosylceramides, sphingomyelin, and their dihydro- 
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counterparts.  LASS5 greatly influenced synthesis of C16:0 dihydroceramides, while 
LASS4 showed a more general preference for C18:0 and C20:0 species.   
 
 Figure 4.6. Ceramides in HEK-293T cells and HEK-293T cells transiently    
                               over-expressing LASS4 and LASS5. 
  
Further work demonstrated LASS5 to be an actual DHCerS 
59
.  HA-tagged 
LASS5 was immuno-purified and assayed for activity with palmitoyl-CoA and stearoyl-
CoA.  The purified LASS5 was shown to have a higher preference for palmitoyl-CoA.  
Thus, combinatory studies between “sphingolipidomics” and more traditional 
biochemical methodologies were able to identify a family of genes through homology, 
characterize the sphingolipids they influenced, determine their susceptibility to an 
inhibitor, and lend direction to enzymatic classification. 
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D. Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and 
in vivo by ceramide synthase to form cytotoxic N-acyl-
metabolites. 
            Seiferlein M, Humpf HU, Voss KA, Sullards MC, Allegood JC, Wang E, Merrill   
            AH Jr. 
            Mol Nutr Food Res. 2007 Sep;51(9):1120-30. 
 
Abstract 
Fumonisins B1 and B2 (FB1 and FB2) are the most abundant members of the 
fumonisins--mycotoxins that are produced by Fusarium verticillioides and are natural 
inhibitors of ceramide synthase. Their hydrolyzed forms, HFB1 and HFB2 (also called 
AP1 and AP2) are found in some foods, and they are not only inhibitors of ceramide 
synthase but also undergo acylation by this enzyme. This study characterized the 
conversion of HFB1 and HFB2 by ceramide synthase to their respective N-acylated 
metabolites using rat liver microsomes and palmitoyl-CoA or nervonoyl-CoA as 
cosubstrates, and examined animals that had been dosed with hydrolyzed fumonisins to 
ascertain if acylation occurs in vivo. Using an HPLC-MS/MS method that allowed the 
sensitive and selective detection of the acylation products, both HFB1 and HFB2 were 
found to be metabolized in vitro to nervonoyl- or palmitoyl-HFB1 and -HFB2 (i.e. 
C24:1-HFB1/2 and C16-HFB1/2, respectively). The apparent vmax was considerably 
higher for formation of C24:1HFB1 (157 pmol/min/mg protein) than for formation of 
C16HFB1 (8.7 pmol/min/mg protein). The acylation products also inhibited ceramide 
synthase and significantly reduced the number of viable cells in an in vitro [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)] assay using a human 
colonic cell line (HT29). Furthermore, HPLC-MS/MS analysis of tissues from rats given 
intraperitoneal doses of HFB1 confirmed that formation of N-acyl-HFB1 occurs in vivo 
to produce metabolites with fatty acids of various chain lengths. The contribution of 
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Liquid Chromatography Electrospray Tandem Mass Spectrometry of FBn and APn 
All samples were analyzed by a Perkin-Elmer API3000 Triple Quadrupole Mass 
Spectrometer with a Perkin-Elmer Series 200 autosampler and binary HPLC system 
attached to the ESI source.  
Fragmentation of fumonisins and their aminopentol (AP) derivatives are 
dependent on dehydration and cleavage of the tricarballylic acid (TCA) moieties.  In all 
cases all TCA are cleaved and (n-1) dehydrations occur (i.e. FB1 loses both TCA and 2 
of 3 hydroxyls) (Figure 4.8). 
 





















ion m/z  
Product 
ion m/z  
Declustering 
Potential 







           
FB1  722.4  334.3  70  300  45 
FB2  706.4  336.2  70  300  45 
FB3  706.4  336.2  70  300  45 
AP1  406.4  334.3  45  100  32.5 
AP2  390.2  336.2  45  100  32.5 
AP3  390.2  336.2  45  100  32.5 
 
LC separation 
FBn/APn compounds were separated on a binary LC system Mobile Phase A 
(69:30:1) (v/v/v) Water:Methanol:Acetic Acid with 5mM Ammonium Acetate, and 
Mobile Phase B (99:1) (v/v) Methanol:Acetic Acid with 5mM Ammonium Acetate 
(Figure 4.11). The column used was a Supelco 2.1 x 50 mm (5 micron particles) C18 
column with an initial solvent system of 80:20 (A:B). This was held for 1.0 min, followed 
by a gradient to 60% B over 3.0 min, followed by a 0.5 min linear gradient to 100 % B.  
This 100% condition was held for 0.5 minutes.  Ion source temperature was set to 350°C 
112 
 












Figure 4.9. Reverse phase LC-MS/MS of FB1-3/AP1-2 standards.  
 
The amino-acyl AP1 derivatives were analyzed using a Supelco 5 m id C-16 Amide 
column (Figure 4.10).  The initial condition of 100% A is held for 2 minutes, and then 
followed by a 5 minute gradient to 100 % B.  The 100 % B condition was held for 8 
















Figure 4.10. Reverse phase LC separation of N-acyl AP1.  
 
Rat injection experiments 
 Rats were given intraperitoneal injections by collaborators with 0, 52, 115, and 
230 µg/day of AP1 (control, low, medium, and high dose respectively). Liver tissue had a 
high affinity for C24:1 and C24:0 N-acylations, although C16:0, C18:0, C20, and C22:0 
species were also observed (Figure 4.11).  Samples were extracted using the extraction 
method from chapter 2 after homogenizing the tissues in PBS.  Samples were used as a 

























Figure 4.11 N-acyl AP1 composition in rat liver.  Rats were injected over 5 days with 




E. Imaging MALDI Mass Spectrometry Using an Oscillating Capillary 
Nebulizer Matrix Coating System and Its Application to Analysis of Lipids in 
Brain from a Mouse Model of Tay-Sachs/Sandhoff Disease  
Chen, Y.; Allegood, J.; Liu, Y.; Wang, E.; Cachon-Gonzalez, B.; Cox, T. M.; 
Merrill, A. H., Jr.; Sullards, M. C. Anal. Chem.; 2008; ASAP Article  
 
Abstract 
The quality of tissue imaging by matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) depends on the effectiveness of the matrix deposition, 























article describes the use of an oscillating capillary nebulizer (OCN) to spray small 
droplets of matrix aerosol onto the sample surface for improved matrix homogeneity, 
reduced crystal size, and controlled solvent effects. This system was then applied to the 
analysis of histological slices of brains from mice with homozygous disruption of the 
hexb gene (hexb
-/-
), a model of Tay-Sachs and Sandhoff disease, versus the functionally 
normal heterozygote (hexb
+/-
) by imaging MALDI-MS. This allowed profiling and 
localization of many different lipid species, and of particular interest, ganglioside GM2, 
asialo-GM2 (GA2), and sulfatides (ST). The presence of these compounds was confirmed 
by analysis of brain extracts using electrospray ionization in conjunction with tandem 
mass spectrometry (MS/MS). The major fatty acid of the ceramide backbone of both 
GM2 and GA2 was identified as stearic acid (18:0) versus nervonic acid (24:1) for ST by 
both tissue-imaging MS and ESI-MS/MS. GM2 and GA2 were highly elevated in hexb
-/-
 
and were both localized in the granular cell region of the cerebellum. ST, however, was 
localized mainly in myelinated fiber (white matter) region of the cerebellum as well as in 
the brain stem with a relatively uniform distribution and had similar relative signal 




 brain. It was also observed that there were distinct 
localizations for numerous other lipid subclasses; hence, imaging MALDI-MS could be 
used for "lipidomic" studies. These results illustrate the usefulness of tissue-imaging 
MALDI-MS with matrix deposition by OCN for histologic comparison of lipids in tissues 
such as brains from this mouse model of Tay-Sachs and Sandhoff disease.  
MS, MS/MS, and MS/MS/MS 
Mouse brains were homogenized (10 mg/ml) in 10 mM potassium phosphate 
buffer (pH 7.4) on ice.  The homogenate was extracted via established methods
201
.  The 
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The samples were re-suspended in 1.0 ml of MeOH and analyzed by syringe 
infusion (0.6 mL/h) into an API 4000 QTrap mass spectrometer. Acidic gangliosides and 
sulfatides were examined in negative ion mode, while neutral glycosphingolipids were 
examined in positive ion mode. 
Sulfatides fragment via cleavage and charge retention by their sulfate to yield a 
primary product ion of m/z 96.9.  Precursor ion scans for m/z 96.9 were used to determine 
the potential N-acyl chain length subspecies in each sample.  These scans were performed 
with declustering potential (DP) set to -220 eV and collision energies ranging from -100-
120 eV.  Once individual sulfatide subspecies were identified, ionization conditions were 
optimized for each and enhanced product ion (EPI) scans were performed (fragmentation 
was performed by excitation ion trap as opposed to collisionally induced dissociation in 
Q2).  EPI scans were performed with Q0 trapping set to “on”, a linear ion trap fill time of 
100 ms, and a scan rate of 1000 amu/s. (Figure 4.12). 
Acidic gangliosides fragment via cleavage of their sialic acids as well as other 
glycan-constituents. Collisionally induced fragmentation yields a product ion of m/z 
290.1, which is representative of the sialic acid moiety.  Precursor ion scans for m/z 290.1 
were used to identify the potential N-acyl chain length subspecies within each family of 
acidic gangliosides (i.e. GM1, GD1, GT1).  These scans were performed with 
declustering potential set to -70-100 eV.  The lower DP was required to reduce in-source 
fragmentation of species having multiple sialic acid residues.  Collision energies ranged 
from -55-75 eV with lower collision energies used for species having increasing numbers 
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of sialic acid residues because of the lability of these molecules toward fragmentation.  
Once individual ganglioside subspecies were identified, ionization conditions were 
optimized for each and EPI scans were performed.  EPI scans were performed with Q0 
trapping set to “on”, a linear ion trap fill time of 100 ms, and a scan rate of 1000 amu/s.  
These scans were used to structurally identify the ganglioside species by analyzing the 
carbohydrate cleavages for each species (Figure 4.13A).  MS
3
 scans were also performed 
with Q1 resolution set to “open”, Q0 trapping set to “on”, a linear ion trap fill time of 100 
ms, and a scan rate of 1000 amu/s.  The MS
2
 product ion picked in all cases corresponded 
to the ceramide portion of each ganglioside.  These were then analyzed for sphingoid 
base and fatty acid composition(Figure 4.13B). 
 
 























Figure 4.13 (A) ESI-MS/MS spectrum of m/z 1383 and (B) ESI-MS3 spectrum of the 
1383/564 transition. 




































































































































































species (Figure 4.14).  Neutral gangliosides fragment via cleavage of 
carbohydrate groups.  Due to these groups mainly consisting of hexose and N-acetyl-
hexosamine in these samples, potential subspecies were identified via neutral loss scans 
for hexose and N-acetyl-hexosamine loss (m/z 162 and 203 respectively).  EPI scans were 
performed with Q0 trapping set to “on”, a linear ion trap fill time of 100 ms, and a scan 
rate of 1000 amu/s.  These scans were used to structurally identify the ganglioside species 
by analyzing the carbohydrate cleavages for each species.  MS
3
 scans were also 
performed with Q1 resolution set to “open”, Q0 trapping set to “on”, a linear ion trap fill 
time of 100 ms, and a scan rate of 1000 amu/s.  The MS
2
 product ion picked in all cases 
corresponded to the ceramide portion of each ganglioside.  These were then analyzed for 
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Perspectives for the future 
 
Initially described and named in 1884 by J.L.W. Thudichum
1
, sphingolipids are 
now known to mediate many important cellular processes, such as apoptosis, 
differentiation, and chemotaxis
202-204
. The structural diversity of SL has been established 
by numerous chromatographic separation techniques, including TLC and HPLC. Mass 
spectrometry provides many advantages in the detection of SL, these include: sensitivity, 
specificity, and structural information (MS/MS).  An additional advantage of MS and 
MS/MS is the ability to detect or quantitate multiple analytes in a single sample. This 
allows multi-component analysis and the extensive metabolic interconversion of SL can 
be monitored. Resolution with TLC and HPLC before MS or MS/MS analysis provides 
an additional criterion (relative mobility or retention time) for identification.  It also 
allows differentiation of isobaric and isomeric species while reducing ionization 
suppression, which may dramatically effect subsequent quantitation. 
Methodologies which employ the strictest analytical standards for detection and 
quantitation will continue to be explored as newer instrumentation and techniques 
becomes available.  Comparisons of pre-existing ionization and fragmentation 
techniques, such as evaluating the behavior of SL in triple quadrupole and quadrupole 
linear ion trap mass spectrometers will be required.  Developing methodologies such as 
ion mobility, tissue imaging, and nano-scale separations hold promise for further gains in 
separations, localizations, and sensitivity in the analysis of sphingolipids. 
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Stable isotopic labeling will remain a valuable technique for tracking 
metabolomic changes within biological samples; however, the field must explore 
localization of sphingolipids because macromolecular complexes and substrate 
availability will elucidate cellular behavior and aid in the explanation of variance in 
cellular SL composition. To accomplish these goals continued expanse in the interaction 
between mass spectrometrists and biologists will further the understanding of the 
sphingolipidome.  
 In spite of the last century's advances in the detection, structural elucidation, and 
quantitation of SL, important challenges remain unsolved. The numerous roles of GSL, 
the most structurally elaborate sphingolipids, are being uncovered by many groups. 
Stable isotopes are being used to trace SL metabolic flux, and at least one mathematical 
model of this flux has also been developed 
205
.  Connections between SL and non-SL 
signal transduction cascades are being reported
206
. However, the location, timing, and 
regulation of changes in SL metabolic flux (the status of the sphingolipidome) remain 















IONIZATION AND FRAGMENTATION CONDITIONS FOR 
SPHINGOLIPIDS 
 
Table A.1. API 3000 Mass Spectrometer Settings for Long Chain Bases and 





DP (V) FP(V) CE (V) R
2
 
d17:1 So 286.4 250.3 30 180 28 0.996 
d17:0 Sa 288.4 252.4 30 180 28 0.993 
d18:1 So 300.4 264.4 30 180 35 0.997 
d18:0 Sa 302.4 266.4 30 180 35 0.997 
d17:1 S1P 366.4 250.3 30 180 30 0.999 
d17:0 Sa1P 368.4 252.4 30 180 30 0.992 
d18:1 S1P 380.4 264.4 30 180 35 0.994 
d18:0 Sa1P 382.4 266.4 30 180 35 0.991 
 
 
Table A.2. ABI 4000 Mass Spectrometer Settings for Long Chain Bases and 





DP (V) CE(V) CXP (V) R
2
 
d17:1 So 286.4 268.3 40 15 15 0.999 
d17:0 Sa 288.4 60.0 50 45 9 0.995 
d18:1 So 300.4 282.4 40 21 16 0.996 
d18:0 Sa 302.4 60.0 50 50 10 0.994 
d17:1 S1P 366.4 250.3 50 23 16 0.994 
d17:0 Sa1P 368.4 252.2 50 25 16 0.997 
d18:1 S1P 380.4 264.4 50 25 16 0.993 
d18:0 Sa1P 382.4 266.4 50 25 16 0.998 
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Table A.3. API 3000 Mass Spectrometer Settings for Complex Sphingolipids and 
Linear Regressions for 0.5 pmol to 1 nmol     









       
 C12:0 486.6 264.4 40 220 35 0.996 
 C16:0 538.7 264.4 40 220 40 0.997 
 C18:0 566.7 264.4 40 220 42.5 0.999 
 C24:1 648.9 264.4 40 220 45 0.998 
 C24:0 650.9 264.4 40 220 45 0.997 
 C25:0 664.9 264.4 40 220 47.5 0.999 
DHCer 
(d18:0) 
      
C16:0 540.7 266.4 40 220 40 0.996 
 C18:0 568.7 266.4 40 220 42.5 0.992 
 C24:1 650.9 266.4 40 220 45 0.997 
 C24:0 652.9 266.4 40 220 45 0.996 
GlcCer 
(d18:1) 
       
 C12:0 644.6 264.4 50 300 45 0.991 
 C16:0 700.7 264.4 50 300 50 0.994 
 C18:0 728.7 264.4 50 300 52.5 0.996 
 C24:1 810.9 264.4 50 300 60 0.990 
DHGlcCer 
(d18:0) 
       
 C12:0 646.6 266.4 50 300 45 0.992 
 C16:0 702.7 266.4 50 300 50 0.993 
 C18:0 730.7 266.4 50 300 52.5 0.997 
 C24:0 814.9 266.4 50 300 60 0.994 
SM 
(d18:1) 
       
 C12:0 647.7 184.4 20 200 40 0.999 
 C18:0 731.8 184.4 20 200 45 0.999 
 C24:0 815.9 184.4 20 200 50 0.998 
DHSM 
(d18:0) 
       
 C12:0 649.7 184.4 20 200 40 0.998 
 C18:0 733.8 184.4 20 200 45 0.997 
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 C12:0 562.6 264.4 40 220 45 0.992 
 C16:0 618.7 264.4 40 220 50 0.990 




       
 C16:0 564.6 266.4 40 220 50 0.994 




       
 C12:0 560.6 78.9 -35 -180 70 0.993 
 C16:0 616.7 78.9 -35 -180 75 0.991 




       
 C16:0 562.6 78.9 -35 -180 75 0.999 
 C24:0 730.9 78.9 -35 -180 80 0.992 
Sulfatide 
(d18:1) 
       
 C12:0 722.4 96.9 -55 -140 110 0.999 
 C16:0 778.6 96.6 -55 -140 115 0.993 
 C24:0 890.9 96.9 -55 -140 120 0.995 
LacCer 
(d18:1) 
       
 C12:0 806.6 264.4 40 220 50 0.991 
 C16:0 862.7 264.4 40 220 55 0.995 











Table A.4. ABI 4000 Mass Spectrometer Settings for Complex Sphingolipids and 
Linear Regressions for 0.5 pmol to 1 nmol   





       
 C12:0 486.6 264.4 55 35 15 0.994 
 C16:0 538.7 264.4 55 37.5 15 0.997 
 C18:0 566.7 264.4 55 37.5 15 0.992 
 C24:1 648.9 264.4 55 42.5 15 0.996 
 C24:0 650.9 264.4 55 42.5 15 0.997 
 C25:0 664.9 264.4 55 45 15 0.997 
DHCer 
(d18:0) 
      
C16:0 540.7 266.4 55 37.5 15 0.990 
 C18:0 568.7 266.4 55 37.5 15 0.995 
 C24:1 650.9 266.4 55 42.5 15 0.989 
 C24:0 652.9 266.4 55 42.5 15 0.992 
GlcCer 
(d18:1) 
       
 C12:0 644.6 264.4 35 42.5 15 0.996 
 C16:0 700.7 264.4 35 45 15 0.995 
 C18:0 728.7 264.4 35 47.5 15 0.995 
 C24:1 810.9 264.4 35 55 15 0.987 
DHGlcCe
r (d18:0) 
       
 C12:0 646.6 266.4 35 42.5 15 0.995 
 C16:0 702.7 266.4 35 45 15 0.990 
 C18:0 730.7 266.4 35 47.5 15 0.998 
 C24:0 814.9 266.4 35 55 15 0.986 
SM 
(d18:1) 
       
 C12:0 647.7 184.4 45 40 10 0.997 
 C18:0 731.8 184.4 45 45 10 0.996 
 C24:0 815.9 184.4 45 50 10 0.999 
DHSM 
(d18:0) 
       
 C12:0 649.7 184.4 45 40 10 0.999 
 C18:0 733.8 184.4 45 45 10 0.994 






       
 C12:0 562.6 264.4 40 45 15 0.996 
 C16:0 618.7 264.4 40 47.5 15 0.993 




       
 C16:0 564.6 266.4 40 47.5 15 0.992 




       
 C12:0 560.6 78.9 -120 -60 -15 0.996 
 C16:0 616.7 78.9 -120 -65 -15 0.993 




       
 C16:0 562.6 78.9 -120 -65 -15 0.998 
 C24:0 730.9 78.9 -120 -72.5 -15 0.995 
Sulfatide 
(d18:1) 
       
 C12:0 722.4 96.9 -220 -100 -15 0.994 
 C16:0 778.6 96.6 -220 -110 -15 0.999 
 C24:0 890.9 96.9 -220 -125 -15 0.995 
LacCer 
(d18:1) 
       
 C12:0 806.6 264.4 45 55 15 0.990 
 C16:0 862.7 264.4 45 60 15 0.987 




























Figure A2.1 Fragmentation Mechanism for A) sphingoid bases and 
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